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a.um I 
Ia GENERAL ASPECTS 
Patients with neuromuscular disorders encountered on the ICU can be 
divided into two main categories. One category has been admitted to the 
intensive care unit (ICU) due to an underlying neuromuscular disorder, 
mainly the Guillam Barre Syndrome ( GBS) and myasthenia gravis. The other 
category develops a so-called acquired neuromuscular disorder during their 
stay on the ICU after admission for other reasons (multi-trauma, severe 
infections, (multiple) organ dysfunction, etcetera). In these patients the 
neurological symptoms mainly consist of muscle weakness, wasting, and 
difficulties in weaning from the artificial respirator. The muscle weakness 
acquired in the ICU can be due to: 
I) A polyneuropathy known as critical illness polyneuropathy, which is an 
axonal motor or sensomotor polyneuropathy. The myopathic changes in 
the histopathology of a notable part of the patients led to the use of the 
more descriptive term critical illness polyneuropathy and myopathy 
( CIPNM) [ De Letter 2 0 0 0 a]. 
2) A neuromuscular transmission defect due to a transient neuromuscular 
blockade related vvith the use of neuromuscular blocking agents. 
3) A myopathy consisting of: a) Critical illness myopathy [Gutmann !999, 
Hund 1999] in which both electrophysiological and histopathological 
features are consistent with a myopathy only. As this is mostly not the 
case we consider them as part of CIPNM. b) Myopathy vvith thick filament 
loss or acute quadriplegic myopathy (AQM) [Danon 1991, Douglas 1992, 
Hirano 1992, Lacomis 1996] and c) acute necrotizing myopathy of 
intensive care [Bolton 1994, Ramsay 1993, Zochodne 1994]. 
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POLY}.!EI)ROPAUUES ENCO;..~ :K Tr:l' N:Th!SIVE CARE UN:T 
Ib CLINICAL AND ELECTROPHYSIOLOGICAL FEATURES OF CIPNM 
The most frequent cause of the acqillred neuromuscular disorders in the ICU 
is critical illness polyneuropathy and myopathy. The first reports on critical 
illness polyneuropathy were published in the early eighties by Bolton, Op de 
Caul, Roelofs and Couturier. These patients were admitted to the ICU, 
required artificial respiration and multiple drugs such as sedatives, 
neuromuscular blocking agents [Gooch 1991, Kupfer 1991, Op de Caul 
19851!991, Rossiter 1991, Subramony 1991], steroids [Lacomis 1996, Mac 
Farlane 19 77] and antibiotics [Sokol! 19 81]. 
The clinical features of CIPNM are muscle weakness and wasting, decreased 
or absent tendon reflexes and difficulties in weaning from the artificial 
respirator. Due to the variability of its clinical features CIPNM can easily be 
overlooked following a prolonged stay on the ICU [Coackley 1992]. The 
muscle weakness is most prominent in the lower extremities and located 
more distally than proximally. The exact onset of these symptoms can be 
difficult to determine due to the use of neuromuscular blocking agents or 
sedatives. About three days after discontinuation of neuromuscular blocking 
agents both clinical and electrophysiological testing of the motor functions is 
reliable and the motor symptoms become evident. In many cases difficulties 
in weaning from the artificial respirator is the presenting symptom of 
CIPNM and the reason to consult the neurologist. Muscle wasting is observed 
in one third of the patients [Zifko 1998]. Tendon reflexes are usually absent, 
but are not a prerequisite for the diagnosis [Hund 1996]. Sensory symptoms 
are often difficult to test in the sedated or intubated patients on the !CU. The 
presence of pain or paresthesias however often suggests a polyneuropathy 
secondary to the use of metronidazole, which primarily affects the sensory 
nerve fibers [Witt 1991]. Zifko eta! [1998] found that in 17 of the 62 
patients with CIPNM (27%) reliable information about sensory function 
could be obtained. Ten of them had distal, symmetric hypesthesia. Impaired 
consciousness, suggestive for an encephalopathy is often present, which 
makes clinical testing even more difficult. Leyten et aJ (1997) found that the 
sensitivity of the clinical judgment of CIPNM was 60% as compared to 
concurrent EMG diagnosed polyneuropathy. 
Critical illness polyneuropathy is often preceded by critical illness 
encephalopathy, which is a poorly recognized entity. The clinical features of 
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CHAI'TER I 
the encephalopathy are impaired attention, concentration, orientation and 
writing [Jackson 1985, Young 1990], the presence of excessive theta activity 
on the EEG may be helpful in the diagnostic process [Young 1992]. 
Electrophysiological testing demonstrates a decrease of amplitudes of the 
compound muscle action potentials within one week of onset of CIPNM. 
Conduction velocities, distal motor latencies and responses to repetitive nerve 
stimulation are normal. The sensory conduction study can show decreased 
sensory nerve action potential amplitudes, which also confirms the presence 
of an axonal polyneuropathy. Such information is usually obtained by serial 
monitoring. 
Needle electromyography reveals spontaneous activity of muscle fibers in rest 
and is present more abundant in distal than in proximal muscles. 
Spontaneous activity of the muscle fibers is usually present 3 weeks after start 
of artificial respiration [Bolton 1996], but can be found within the first two 
weeks [Op de Coul 1991]. Sometimes there are signs of myopathic changes 
of the motor unit potentials with a short duration and low amplitudes on 
voluntary activation. 
Diaphragm and chest wall needle electromyography has been performed in 
patients who presented with failure to wean from the ventilator; this showed 
also spontaneous activity of the diaphragm [Bolton 1993a, Zifko1998]. 
Dysfunctioning of the neuromuscular junction in the ICU due to a 
preexisting disorder or the toxic effect of neuromuscular blocking agents or 
aminoglycosides can be excluded by repetitive nerve stimulation [Segredo 
1992]. For suspected disturbances of the spinal dorsal columns the somato-
sensory evoked potentials can be tested. 
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Ic VARIANTS OF CIFNM 
As critical illness is not necessarily associated with artificial respiration, this 
should mean that CIPNM also occurs outside the ICU. Reports of 
polyneuropathy in patients suffering from severe burns and SIRS were 
described by De Saint Victor et al [1994]. Gorson and Ropper [1993] 
reported the development of critical illness polyneuropathy in five patients 
with severe respiratory problems, who· later required artificial respiration. 
The severe sub-acute mainly motor axonal polyneuropathy that occurs in 
end-stage renal disease with trauma or sepsis may also be considered as a 
variant of CIP!-.'M [Young 1990]. 
Id DIFFERENTIAL DIAGNOSIS OF POLYNEUROPATHIES 
ENCOUNTERED IN THE ICU 
• Critical illness myopathy 
There has been much debate as to the incidence of a myopathy, which may 
occur independently or in association with a polyneuropathy in critical 
illness patients [Hund 1999]. It is often difficult to distinguish between 
a:>conal motor polyneuropathy and myopathy in CIPNM. Clinical testing of 
the sensory function is often not reliable and therefore is not helpful either 
in the differential diagnosis. Theoretically predominant proxinlal weakness, 
neck fl.e..xor weakness and facial weakness occur more often in patients with 
myopathy. In the needle electromyography low amplitudes and short 
duration of the motor unit potentials suggest a myopathy. Normal sensory 
nerve action potentials (SNAP) amplitudes and decreased compound motor 
action potential (CMAP) amplitudes are usually present in conduction 
studies. However absence of or a decrease in SNAP amplitudes does not 
exclude a myopathy. Because of tissue edema, SNAP amplitudes may be 
spuriously low. Serial studies may reveal a significant fall in SNAP amplitudes 
in critical illness polyneuropathy. Reliable examination of the motor unit 
potentials (MUP) on voluntary activation is also difficult in cases of severe 
muscle weakness. Rich eta! [1997] described that in neuropathy or endplate 
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dysfunction the excitability of the muscle remains normal, which appeared 
not to be the case in acute quadriplegic myopathy. Direct muscle stimulation 
may therefore be helpful in the distinction of polyneuropathy and myopathy. 
Determination of creatinine phosphokinase in serum is also helpful in 
revealing a myopathy. Highly elevated levels of creatinine phosphokinase 
suggest a necrotizing myopathy. Furthermore severe myopathy is associated 
with myoglobinurea. At present the best method to differentiate between 
underlying polyneuropathy and myopathy is by performing a muscle biopsy 
using standard light microsopic examination of the muscle tissue. 
• Guillain Barre Syndrome 
The Guillain Barre Syndrome (GBS) is a (sub-) acute immune-mediated 
polyneuropathy. Clinical features required for diagnosis are I) progressive, 
more or less synunetrical motor weakness of more than one limb. The degree 
ranges from minimal weakness to paralysis of the muscles of all four 
extremities. the trunk, bulbar and facial paralysis and external 
opthalmoplegia. II) Areflexia: universal areflexia is the rule, though distal 
areflexia with definite hyporefle.'da of the biceps and knee jerks will suffice if 
other features are consistent. The diagnostic criteria are based on clinical, 
laboratory and electrodiagnostic criteria and are defined by Asbury and 
Comblath (1990). 
To distinguish CIPNM from the acute motor axonal variant of Guillain-Barre 
syndrome the following characteristics may be useful [De Letter 2000b]: 
I) GBS is the primary neurological reason of admission to the intensive care 
unit (ICU). CIPNM on the other hand develops during a patient's stay on 
the ICU for another reason. Development of GBS on the ICU is considered 
to be very rare. 
2) Infectious symptoms like fever and diarrhea have usually subsided before 
the clinical features of GBS appear. 
3) The characteristic alterations in the cerebrospinal fluid of GBS patients with 
a raised protein and normal to slightly elevated cell count. 
4) The possibility to detect IgG anti-bodies against GMI, GM!b, GD!a and 
N-acetylgalactosarninyl-GD!a in the serum of patients with acute motor 
neuropathy. 
5) Electrodiagnostic changes in GBS occur in both sensory and motor nerves 
in about 80% of the patients in the Western world. In CIPNM there is 
clinically predominantly motor dysfunction. Both CIPNM and axonal type 
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GBS show sensomotor or pure motor axonal features. CIPNM can 
sometimes be distinguished from GBS by the presence of myopathic 
motor unit potentials on voluntary activation. 
6) During the progression of GBS the demyelinating features of the nerve 
conduction study may change into a secondary axonal pattern. In the 
latter slow nerve conduction velocity remains in some patients and the 
initial needle electromyographic study lacks spontaneous activity [Chen 
1998]- In CIPNM spontaneous activity of the muscle fibers is an early 
feature. Further phrenic nerve conduction studies usually show no 
significantly prolonged latencies in CIFNM [Bolton 1986]-
7) Severe autonomic disturbances are more common in GBS than in CIFNM 
[Bolton 1986]-
8) Septic encephalopathy may be present before onset of CIPNM. Patients 
with GBS do not exhibit disturbed consciousness. 
7 
• Porphyric Neuropathy 
Porphyric neuropathy is an acute or subacute predominantly motor 
neuropathy. Disturbances of porphyrin metabolism are associated with acute 
attacks of neurologic disease in case of hepatic porphyrias. These porphyrias 
consisting of acute intermittent porphyria (AIP), hereditary coproporphyria 
(HCP) and variegate porphyria (VP) are caused by enzyme defects 
( uroporphyrinogen-1-synthetase, coproporphyrinogen oxidase or 
protoporphyrinogen oxidase). AlP [Kappas 1983, Stein 1970], HCP 
[Magnussen 197 5] and VP [Eales 1980] all have a genetic origin. The attacks 
of acute hepatic porphyrias may be precipitated by drugs (most often 
barbiturates, estrogens, ethanol excess, griseofulvin, hydantoins, 
meprobamate, oral contraceptives and sulfonamides), hypoglycemia and 
hormonal influences. The latter results in the occurrence of AlP in the luteal 
phase of the menstrual cycle. Hormone-induced AlP does not occur before 
puberty in either sex. The excess of heme precursors that is being produced 
during the attacks is detectable in urine, feces and blood. Therefore they 
serve as diagnostic tools for the specific types of porphyria [Windebank 
1993]. 
The change of color of the urine is due to the oxidation of the 
porphyrinogens. The conversion to the corresponding porphyrin causes the 
urine to turn red or purple. Porphobilinogen may polymerize to porphobilin, 
which has a black color. 
The clinical features are: 1) Acute colicky abdominal pain. It is not known if 
the pain is caused by local effects of heme precursors or heme deficiency on 
muscles and nerves of the gastrointestinal tract or to acute autonomic 
neuropathy with sympathetic hyper reactivity. The latter is a prominent 
feature during porphyric attacks. 2) Psychiatric disturbances that vary from 
restlessness and agitation to psychosis, coma and seizures. 3) Acute 
neuropathy that develops within 2-3 days of onset of abdominal and 
psychiatric symptoms. The first symptoms may be back or limb pain. As in 
CIPNM motor symptoms are the earliest and most prominent clinical features. 
However in porphyric neuropathy the weakness is occasionally asymmetric or 
patchy, may begin in the upper limbs or cranial nerves (commonly facial 
weakness and swallowing difficulty), and proximal muscle are as likely to be 
affected as the distal ones. Atrophy is seen early as in CIPNM, may be severe, 
and is probably due to axonal degeneration and generalized weight loss. 
Sensory symptoms are less prominent but may involve patchy or migratory 
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painful paresthesias. Progression to maximal deficit, with possible respiratory 
insufficiency, usually occurs in a few days, but may occur gradually during a 
period of several weeks. 
Electrophysiology of this acute neuropathy may show normal nerve 
conduction studies and needle electromyography during the first few days of 
the illness. As in CIPNM the primary process in porphyric neuropathy 
involves an axonal degeneration resulting in a decrease of the compound 
action potentials, which is usually proportional to the severity of muscle 
weakness. There is no prominent sensory involvement except when 
degeneration of the majority of motor axons occurs and during the 
regeneration phase slowing of the conduction velocity is present. Somata 
sensory evoked potentials and spinal motor-evoked potentials are useful as 
proximal and cranial innervated muscles are mostly involved. Needle 
electromyography of clinically involved muscles reveals denervation 
potentials in 5-10 days and features of reinnervation during recovery 
[Windebank 1993]. 
The following features may be used to disciminate the clinical pictures of 
porphyric neuropathy and CIPNM: 
1) Porphyric neuropathy shows prodromal abdominal and psychiatric 
symptoms. 
2) Porphyric neuropathy patients may have a family history of porphyric 
attacks. 
3) CIPNM occurs during the patient's stay on the ICU for other reasons, the 
porphyric patient that develops neuropathy may become respiratory 
insufficient and therefore be admitted to the !CU. 
4) Porphyric neuropathy patients have asymmetric or patchy weakness 
beginning in upper limbs or cranial nerves, CIPNM patients have 
symmetrical tetraparesis and occasionally involvement of cranial nerves. 
5) E.xcretion of heme precursors causes the described color changes in urine. 
6) Avoiding drugs that induce cytochrome p450 and situations leading to 
hypoglycemia can prevent porphyric attacks. Treatment is possible for the 
underlying defect using heme intravenously. 
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Ie AIMS OF THE PROSPECTIVE STUDY OF CIFNM 
CIPNM has only a short history and interest arose to analyze the 
epidemiological, clinical, electrophysiological and pathological features of this 
disease. In a prospective study on the ICU we compared the clinical and 
electrodiagnostic characteristics of patients that developed CIPNM with 
patients that did not. After a pilot study on CIPNM in the St Elisabeth 
Hospital Tilburg performed by Freek Verheul [1994], the prospective study 
performed by Marie-An de Letter outlined in this thesis of 98 patients started 
in 1994. One of the aims of the study was to determine risk factors for 
developing CIPNM (Ch II)_ Therefore variables such as patient characteristics, 
medication and scores that express severity of illness were used. Defmed risk 
factors were analyzed to identify patients that are at low. medium or high 
risk of developing CIPNM. Chapter III describes the natural history of CIPNM, 
its clinical and electrophysiological aspects. Further clinical variables, patient 
characteristics, medication and neuro-pathological features were compared 
with the severity of disease in an attempt to identify prognostic factors. In 
addition to an introduction on the process of immune activation in critically 
ill patients in general (Ch IV), chapter IV b describes the structural changes in 
the muscle tissue of CIPNM patients compared with some ICU patients that 
did not develop CIPNM. This neuro-pathological analysis consisted of 
standard light microscopical examination of the muscle tissue and tested the 
presence of immune activation. The neuropathological findings were also 
analyzed statistically to exclude the influence of systemic (inflammatory) 
variables. In chapter V a general discussion is presented high-lighting the 
strong and weaker aspects of this prospective study with recommendations 
for future research. 
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II 
Risk factors for the development of 
polyneuropathy and myopathy in 
critically ill patients 
C-f.APTI'Jt II 
INTRODUCTION 
Critical illness polyneuropathy and myopathy (CIPNM) is a neuromuscular 
disorder that has been recognized in critically ill patients [Bolton 1993c, 
Latronico 19 96]. The clinical picture consists of difficulty in weaning from 
the artificial respirator, tetraparesis and muscle wasting of the limbs. The 
tendon reflexes are mostly decreased or absent. The neurophysiological 
examination shows an axonal polyneuropathy and sometimes myopathic 
altered motor unit potentials. The morphological features in the nerve point 
to a primarily distal axonal degeneration of motor and sensory fibers 
[Zochodne 1987]. Muscle biopsy shows scattered atrophic fibers in acute 
denervation and grouped atrophy in chronic denervation. Also necrotic 
muscle fibers can be found suggesting the contribution of a myopathy or a 
primary myopathy [Latronico 1996,0p de Caul 1991]. On clinical and 
electrodiagnostic grounds neuromuscular complications in the critically ill 
patients may be due to a polyneuropathy or myopathy. Since it is not always 
possible to differentiate between an axonal motor neuropathy and myopathy 
[Gutmann 1999), we prefer to use the descriptive term critical illness 
polyneuropathy and myopathy. 
Hypotheses regarding the etiology of CIPNM include a role for (I) the 
presence of the systemic inflammatory response syndrome (SIRS) or sepsis 
and its influence on activation of the body defense system [Latronico 
1996,Zochodne 1987, Leijten 1995, Wijdicks 1994b, Hund 1997, Witt 
1991) or (2) a combination of (!) and neuromuscular blocking agents 
(NBA) with or without steroids [Op de Coul1991, Bolton 1996]. Also other 
conditions as malnutrition, underlying disease, immobility and drugs used in 
the ICU have been postulated [Coackley 1993]. Because of this controversy, 
we prospectively followed critically ill patients. After inclusion into the study 
systematically serial clinical, laboratory and electrophysiological studies were 
performed. In that way we were able to diagnose CIPNM at an early stage 
and could compare the characteristics of these patients with patients who did 
not develop CIPN"M. 
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METHODS 
In a longitudinal prospective observational study at the intensive care unit of 
the St. Elisabeth Hospital Tilburg 98 patients were included in the period 
from May 1994 to July 1996. The medical ethical committee of the hospital 
approved the study. 
Patients could be included from day 4 of the artificial respiration after a 
written informed consent was obtained from the family of the patient. The 
exclusion criteria for this study were the presence of a Guillain-Barre 
syndrome. acute or chronic spinal cord lesion. hypophosphataemia, 
myasthenia gravis and a history of a pre-existing disease, which might be 
responsible for the development of polyneuropathy or myopathy. 
After the patients were enrolled, they underwent clinical and 
electrophysiological monitoring. The neurological examination was 
performed twice a week during the stay in the intensive care unit and once a 
week in the general ward until recovery. The examination assessed motor 
deficit, muscle wasting, sensory loss and tendon reflexes. Motor sum score of 
three upper and three lower limb muscles was used to evaluate muscle 
weakness. This involved the deltoid, biceps, wrist extensor, iliopsoas, 
quadriceps femoris and the foot extensor muscles on the most affected side if 
paresis was asymmetric (ma.-ximum score 30 in non-comatose patients). In 
the non-cooperative only tendon reflexes and motor sum score on pain 
stimuli were scored consisting of flexion in the elbow and flexion the hip, 
with a ma..'dmum sum score of 10. 
For the clinical assessment of CIPNM only the motor sum score and tendon 
reflexes counted at least three days after the use of neuromuscular blocking 
agents was stopped (Table I). 
Electrophysiological monitoring was performed on day 4, II and 25 after 
start of the artificial respiration and consisted of conventional orthodromic 
motor (ulnar and peroneal) and antidromic sensory (ulnar and sural) nerve 
conduction studies. If edema was present the results of decreased CMAP or 
SNAP amplitudes were not used for analyses. The ulnar and peroneal nerve 
conduction studies were performed also along the elbow segment and at the 
fibula to exclude underlying entrapment neuropathies. Limb temperature was 
registered and warming was performed until limb temperature of at least 3 2 ° 
Celsius. 
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Table 1: Clinical and electrophysiological criteria of CIPNM. 
Patients used no neuromuscular blocking agents for at least three days for 
both clinical and electrophysiological criteria. For diagnosis of CIPNM clinical 
and electrophysiological criteria should be met. 
Clinical; present in at least tvvo consecutive visits. 
Co-operative patient 
• Motor sum score <26. 
• Decreased or absent tendon reflexes. 
Non co-operative patient. 
• Motor sum score < 8. 
• Decreased or absent tendon reflexes. 
Electrophysiological 
Presence of axonal polyneuropathy defmed as in I or II: 
I distal CMAP ulnar nerve absent or below <4.2 mV and entrapment at the 
elbow and demyelination* were excluded. 
and 
distal CMAP peroneal nerve absent or below <2.6 mV and entrapment 
at the fibular head and demyelination* were excluded. 
II Criteria for ulnar or peroneal nerve as mentioned above 
and 
Spontaneous activity of the muscle fibers in rest (fibrillations or positive 
waves) in at least two of the examined muscles. 
• Ratio of the area of the proximal CMAP versus the distal GvrAP >0.89, 
in the nerve with decreased CMAP amplitude. 
Furthermore repetitive nerve stimulation at 3 Hz of the ulnar nerve and 
monopolar needle electromyography of the biceps, abductor digiti quinti, 
quadriceps femoris and tibialis anterior muscle were performed. When 
patients suffered from disability due to CIPNM neurological and 
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electrophysiological examinations were repeated every 6 weeks. Both the 
clinical and electrophysiological criteria had to be met for the diagnosis of 
CIPNM (Table I). 
The use and dosage of midazolam, vecuronium and steroids were registered 
at every visit. The use of aminoglycosides was noted at entry. The creatinine 
phosphokinase, erythrocyte sedimentation rate and liverfunctions were tested 
weekly. If a patient developed clinical or electrophysiological signs of a 
neuromuscular disorder the myoglobin in the urine was analyzed. 
At entry the Apache-III score, sepsis severity score and presence of SIRS were 
determined. Developing SIRS during the stay on the ICU was also noted. The 
Apache-III score, the Acute Physiology, Age, Chronic Health Evaluation, is a 
methodology that is known to predict hospital mortality risk for critically ill 
hospitalized adults [Friedland 1996, Knaus 1991]. The score results from 
addition of three groups of variables concerning physiology, age and chronic 
health. The physiology is represented in weighted laboratory abnormalities 
and vital signs: pulse, mean bloodpressure, temperature, respiratory rate, 
Pa02 , hematocrit, white blood cell count, creatinine, urine output, blood 
urea nitrogen, sodium, serum albumin, bilirubin, glucose [Knaus 1991]. 
The sepsis severity score consists of scoring five organ systems (lungs, heart, 
liver, kidneys, intestine) and the blood coagulation on a scale of 0 to 5 of 
which 5 reflects the worst situation. Eventually the three highest of these six 
scores are put to a square and summated resulting in the sepsis severity score 
(minimum 0 and maximum 7 5) [Stevens 1983]. The presence of SIRS 
includes two or more of the following clinical manifestations: (!) body 
temperature greater than 38°C or less than 36°C; (2) heart rate greater than 
90 beats per minute; (3) tachypnea, manifested by respiratory rate greater 
than 20 breaths per minute, or hyperventilation as indicated by PaC02 of less 
than 3 2 mm Hg; and ( 4) alteration in the white blood cell count, such as a 
count greater than 12,000/ cu mm, a count less than 4,000/ cu mm, or the 
presence of more than 10 percent immature neutrophils [Bone 1992]. 
Statistical analysis 
The Apache-III score, the presence of SIRS, the reason of admission, the 
sepsis severity score and its components were related at entry with the 
fraction of patients that developed CIPNM from entry (day 4 of the artificial 
respiration) using the Kaplan-Meier method and the log rank test. This was 
also done for the use of aminoglycosides at entry and the dosage of 
IS 
midazolam, vecuronium, and steroids at entry and until day 7 of the artificial 
respiration when still no CIPNM was diagnosed. Day 7 was chosen because at 
that time only one case of CIPNM had been diagnosed. Analyzing earlier in 
time would be to close to the moment of entry in the study. Finally the total 
dose of vecuronium used until day 7 of the artificial respiration combined 
with the kidney function were related with the fraction that developed 
CIPNM. P-values <0.05 were considered significant. 
The factors studied in the univariate analysis were used in a stepwise Cox's 
proportional hazards modeL With this approach a predictive index was 
calculated using the two eventual significant risk factors. Three groups (low, 
medium and high risk) were determined from the distribution of this index. 
Kaplan-Meier curves are presented, showing the risk of developing CIPNM at 
certain time from start of the artificial respiration for each of the three risk 
groups. 
RESULTS 
From May 1994 to July 1996 117 patients were evaluated of which 98 were 
eligible. Nineteen patients were not eligible of which 11 refused to give 
permission for this study and 8 patients had exclusion criteria. CIPNM 
occurred in 32 (33%) of the 98 prospectively monitored critically ill patients. 
The 95% binominal e-xact confidence interval was 24%-43%. 
Analysis could be performed on the data of 97 of the 98 patients, including 
31 CIPNM patients. 
The clinical characteristics showed 55 (57%) male and 42 (43%) female 
patients. Their median age was 70 years, ranging from 15-85 years. The 
reason of patient admission was a multi-trauma in 13 (13%), elective surgery 
in 38 (39%), infectious disease in 27 (28%) and a category others of 19 
(20%). This last category consisted mainly of patients with severe cardiac 
insufficiency and two patients with exacerbation of their chronic obstructive 
pulmonary disease. 
Univariate analysis revealed the Apache-Ill score (Fig. Ia), the presence of 
SIRS (Fig. Ib) and the use of aminoglycosides as being significant factors for 
the development of CIPNM at entry of the study (Table 2). The sepsis 
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Table 2: Patients characteristics and results of univariate analysis. 
4 days after start Number of Percentages with CIPNM P-value 
of artificial patients 15 days1 30 days1 Log rank test 
respiration 
Overall 97 IS 35 
Apache-III score 90 24 4 17 0.02 
>70-,; 85 30 14 28 
>85 43 22 so 
Sepsis Severity score 10-57 97 0.91 
SIRS Yes 47 20 46 0.04 
:-Jo 50 10 26 
vecuronium 0 mg 66 14 31 0.38 
>0 mg 31 16 43 
midazolam ,;soo mg 51 20 32 0.86 
>500 mg 46 9 38 
steroids 0 mg 70 IS 35 0.67 
>0 mg 27 IS 34 
aminoglycosides Yes 37 22 51 0.049 
No 60 10 26 
7 days after start 
artificial respiration. 
(n=96) 3 
vecuronium 0 mg 62 17 33 0.28 
>0 mg 34 21 48 
midazolam o;!780mg 48 22 35 0.95 
>1780mg 48 16 44 
Steroids 0 mg 67 16 34 0.31 
>0 mg 29 25 48 
1 t'l.ftcr 15 days of artificial respiration. 
2 t'l.ftcr 30 days of artificial respiration. 
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Figure Ia, Ib and II; 
Kaplan Meier curves showing the fraction of patients developing CIPNM 
during 30 days after start of the artificial respiration. Ia: the Apache-ill score 
OS: 70, > 70- OS: 85 and> 85 (p=0.02). Ib: presence or absence of SIRS or no 
SIRS (p=0.04). II: Low-risk group with an Apache-III score OS: 70 and no 
SIRS, the high-risk group with an Apache-III score >85 and presence of SIRS 
and the medium-risk group containing all other patients. 
severity score (also its individual components representing the organ 
functions and the coagulability), the reason of admission, the amount of 
vecuronium, midazolam or steroids used (Table 2), did not show a 
relationship with the occurrence of C!PNM. Nor did the total dose of 
vecuronium used until day 7 of the artificial respiration combined with the 
kidoey function relate with the development of CIPNM. 
SIRS was present in 47 of 9 7 cases ( 48%). There was a clear relationship 
between the presence of SIRS and the use of aminoglycosides (P-value 0.03). 
Using a stepwise proportional hazards model with Apache-ill score, presence 
of SIRS, amount of vecuronium, midazolam and steroids and the use of 
aminoglycosides as potential risk factors, only the Apache-III score and the 
presence of SIRS remained significant. Based on the distribution of the 
predictive index derived from these two variables three risk groups were 
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identified. The low-risk group with an Apache-III score S:70 and no SIRS 
(n=!3). the high-risk group with an Apache-Ill score >85 and presence of 
SIRS (n=22) and the medium-risk group containing the other patients 
(n=62). The Kaplan-Meier curves show that the probability of developing 
CIPNM within 3 0 days of artificial respiration is 8% for the low-risk group. 
28% for the medium-risk and 72% for the high-risk group (Fig. II). 
Although the variables SIRS and Apache-III score are correlated, they both 
appear to contribute to the multivariate Cox regression. 
DISCUSSION 
The incidence of CIPNM in these 98 prospectively studied critically ill 
patients was 33%. In previous studies using similar inclusion criteria this 
varied from 33 to 44% [Leijten 1995,Coakley 1993]. If patients suffer from 
sepsis the incidence increases up to 70% [Hund 1997,Witt 1991,Coakley 
1993] 
Risk factors for the development of CIPNM 
The Apache-III score, presence of SIRS and use of arninoglycosides were all 
significant in the univariate analysis of the exposed risk factors for the 
development of CIPNM. Multivariate analysis showed that the presence of a 
high Apache-Ill score and SIRS both were independent factors contributing to 
the development of CIPNM. When both factors are present the risk was 
found to be 72%. 
With regard to a high Apache-III score this appeared to be an important 
predictor for the development of CIPNM. The Apache-III scoring system is 
used to predict the mortality risk in ICU patients and is a quantitative index 
of disease severity based on clinical and laboratory physiological data 
[Friedland 1996, Knaus 1991]. A high Apache-III score has been associated 
with the development of MODS in patients with perforated viscus [Barie 
199 6]. The group of Bolton et al was the first to relate critical illness 
polyneuropathy with multiple organ failure and sepsis and Bolton 
hypothesized about the pathogenic role of SIRS [Bolton 1993c, Zochodne 
!987, Witt 1991, Bolton 1996]. In this study organ dysfunction is reflected 
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by the APACHE III score giving a quantitive index of disease activity, and the 
results more or less agree with the studies using MODS score [Leijten 199 5]. 
Although in the univariate analysis the use of aminoglycosides at entry was 
related significantly with the development of CIPNM, this was no longer so 
after multivariate analysis. This may be due to the correlation with the 
presence of SIRS. Since in our ICU in case of (threatening) sepsis 
aminoglycosides are standard treatment, it cannot be ruled out that either 
SIRS or aminoglycosides may have a pathogenic effect. However, no effect 
was found on the neuromuscular junction using repetitive stimulation in the 
electrophysiological monitoring of the patients, which would be "'-l'ected in 
case of a neurotoxic effect of aminoglycosides [Sokol! 19 81 J. Furthermore 
we note that the effect of the use of aminoglycosides in the muscle tissue 
was not visible at the light microscopical level in our neuropathological 
study performed on the same population that was studied for the presence of 
risk factors [De Letter 2000a]. More detailed cellular study was not 
performed. Therefore, we consider SIRS more likely as risk factor. 
As no relationships were found for the total amount of midazolam, 
vecuronium or steroids used with regard to developing CIPNM, it seems that 
this medication does not play a role in the pathogenesis. Our previous results 
indicated an important role for neuromuscular blocking agents [Op de Coul 
1985]. However, results were obtained retrospectively in that study. A 
prospective study of Douglass et a! assessing the occurrence of myopathy as a 
complication of therapy of severe asthma in patients requiring mechanical 
ventilation showed that myopathy was associated with a higher total dose of 
vecuronium. It is likely that these patients had an acute quadriplegic 
myopathy with selective loss of thick filaments, which is a different entity 
than CIPNM. In our study we did not include patients with an acute 
quadriplegic myopathy [Douglass 1992]. Our current results agree with 
other prospective studies, which report that drugs do not play a part in 
development of CIPNM on the ICU [Latronico 1996, Leijten 1995, Witt 
1991, Coakley 1993, Berek 1996]. The causative descriptions of mainly 
retrospective case series of prolonged neuromuscular blockade can be divided 
into pharmacokinetically based [Segredo 1990,Shearer 1991, Hoyt 1994, 
Fahey 1981, Lynam 1988, Smith 1987] and neuromuscular function based 
[Shanks 1985, Darrah 1989, Wokke 1988, Vanderheyden 1992, Patridge 
1990]. The pharmacokinetically based blockade is attributed to decreased 
renal clearance of active metabolites of vecuronium. The combination of the 
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amount of vecuroniurn used during the first week of the artificial respiration 
and disturbed kidney functions were not found to be a risk factor for the 
development of CIPNM in our study. Concomitant use of several drugs alters 
the duration of action of NBA' s. Drugs, which we investigated, that can 
potentiate blockade are aminoglycosides and midazolam. Combinations of 
such medication in our study did not reveal any differences between the 
patients that developed CIPNM and those who did not. However the 
influence of the medication as prognostic factors on the recovery of CIPNM 
patients should also be considered. This might support the hypothesis of 
previous publications that such medication especially neuromuscular blocking 
agents are of importance in CIPNM. 
Pathogenetic model 
In the critically ill patients which is reflected in a high Apache-III score, the 
host response seems to lead to dysfunction of the neuromuscular system. On 
the other hand the pro-inflammatory cytokines TNF-cx and IL-l are known to 
play a pivotal role in SIRS. Tissue damage, infection or severe organ 
dysfunction may serve as a trigger inducing antigen presenting cells to 
produce IL-l, IL-6, IL-8, IL-10, IL-12 and TNF-cx, resulting in activation and 
influx of mainly CD4+ Th-cells, monocytes, macrophages and neutrophils. As 
a result of this immune activation adhesion molecules are also being 
produced, leading to an increased vascular permeability [Nieuwenhuijzen 
1997]. Extravasation of (inflammatory) cells, edema and therefore tissue 
damage are the result in various organs; one of them being the 
neuromuscular system. We recently found evidence for immune activation in 
the muscle tissue of our CIPNM patients [De Letter 2000a]. A disturbed 
microcirculation with resulting endoneurial edema and hypoxia may be 
responsible for primary """onal degeneration [Bolton 1996]. 
Our study indicates that critically ill patients with both a high Apache-III 
score and SIRS are most prone to the development of CIPNM (Fig. II), which 
agrees with the pathophysiological model discussed. The high incidence of 
CIPNM of about 70% when patients suffer from sepsis or SIRS as found in 
previous studies supports this hypothesis [Hund 1997 ,Witt 1991, Segredo 
1990]. In conclusion, the risk of developing CIPNM is higher in patients 
with a high Apache-Ill score and the presence of SIRS. So, the more sick the 
patient on initial evaluation, the greater the risk of developing CIPNM. 
22 
RISK FACTORS ~OR THI DEYELOPJ\.1Et>..T 01' POLYNEUROPATHY AND MYO?A-:1--c¥!}; CJUT!C.'.:J.Y ;a PATIDJ:'S 
Practical implications 
The APACHE III scoring system and the presence of SIRS can be useful tools 
in assessing who will be at risk of developing CIPNM on the !CU. Our data 
however need to be validated in a second study. 
Many intensive care doctors use these scores, which are relatively easy to 
obtain. Patients with an initial high APACHE-III score and development of 
SIRS during follow-up should have regular neurological assessments of 
muscle strength. To obtain this one should be careful with the use of 
sedation and NBA' s in these patients. As soon as CIPNM is suspected an EMG 
should confirm these findings and supportive therapy can be started. 
Although NBA' s or steroids are not causing CIPNM it is possible that after 
the onset of CIPNM NBA's or steroids can be detrimental to muscles. 
Moreover, because of the weakness in limb and respiratory muscles due to 
CIPNM NBA's are no longer necessary and should be withheld in these 
patients. This could become an early diagnosis of CIPNM. Most CIPNM 
patients are diagnosed within 2 to 3 weeks after the start of artificial 
respiration, therefore we advise that an EMG be performed at day I 0-14 
after start of ventilation and if necessary I week later if neurological 
assessments are not possible. Difficulty in weaning from the artificial 
respirator was a common reason for asking neurologists to assess whether 
the patient has a CIPNM. In our opinion this is a late sign and with the 
advice mentioned above can be anticipated. Multi-organ failure and sepsis, 
risk factors for CIPNM, probably result in an exaggerated immune response 
with a local (muscle tissue) low-level immune activation as a consequence 
[De Letter 2000a]. It is likely that effective therapy of multi-organ failure and 
sepsis may result in a lower incidence of CIPNM. Immune-modulating 
therapy. like the use of intravenous immunoglobulins, for patients at risk for 
CIPNM could be a theoretical option. A retrospective study gave some 
indication of this [Mohr 1997], but should be tested in a prospective 




A clinical and electrodiagnostic prospective 
study of patients with critical illness 
polyneuropathy and myopathy: 
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INTRODUCTION 
Critical illness polyneuropathy and myopathy (CIPNM) is a neuromuscular 
disorder frequently encountered in the intensive care unit. The incidence of 
CIPN"M varies from 33-40% [Leijten 1995, Coakley 1993] and reaches 70% 
in septic patients [Hund 1997, Witt 1991, Coakley 1993]. The clinical 
characteristics are difficulty in weaning from the artificial respirator, muscle 
weakness and wasting, and decreased or loss of tendon reflexes. We prefer 
to use the descriptive term critical illness polyneuropathy and myopathy 
since it is not always possible to differentiate (clinically and 
electrophysiologically) between an a:'Conal motor neuropathy and myopathy 
[Guttnann 1999]. Furthermore, muscle biopsies of patients with the clinical 
and electrodiagnostic features of critical illness polyneuropathy often show 
myopathic changes [Latronico 1996, De Lettter 2000a]. 
Until recently, it has been stated, that the patients with CIPNM generally 
recover well [Hund1996J. but long term follow-up studies of patients with 
CIPNM are scarce. Moreover, death in critical ill patients may overestimate 
this general accepted good prognosis. Therefore, in a longitudinal 
prospective observational study we followed 98 patients who needed at least 
4 days of artifical respiration. All patients were monitored clinically and 
neurophysiologically for the development of CIPNM. Development of 
clinical and electrophysiological features, the outcome during follow-up, 
assessment of prognostic factors for bad outcome and the correlation of 
clinical characteristics with structural changes in the muscle tissue of 3 0 of 
the 3 2 patients who developed CIPNM are described. 
26 
TilE :>/AlURA: I-I:..TIOP.Y Of. C!PNM 
METHODS 
In the intensive care unit of the St. Elisabeth Hospital Tilburg we monitored 
98 patients of which 32 met the clinical and electrophysiological criteria of 
CIPNM as defined earlier [De Letter 200 I]. 
The exclusion criteria for this study were the presence of a Guillain-Barre 
syndrome, acute quadriplegic myopathy, acute or chronic spinal cord 
lesion, hypophosphatemia, myasthenia gravis and a history of a pre-existing 
polyneuropathy or myopathy. The medical ethical committee of the hospital 
approved the study. 
Monitoring of these patients for the development of CIPKM started four 
days after the onset of the artificial respiration. Written informed consent 
was obtained from the family of the patient. 
Clinical assessment, medication and laboratory monitoring (n=98): 
Clinical data were recorded twice a week during the stay on the intensive 
care unit and once a week in the general ward until discharge from the 
hospital. Clinical monitoring consisted of: 
I) The motor sum score reflected by the MRC sum score of three upper and 
three lower limb muscles. This involved the deltoid, biceps. wrist 
extensor, iliopsoas, quadriceps femoris and the foot extensor muscles on 
the most affected side if paresis was asymmetric (ma.'illnum score 30). 
2) Touch and pain sensation were tested in all extremities and classified as 
normal, disturbed (in upper, lower or all extremities) or unreliable. 
3) The presence of muscle wasting defmed as absent, present or unreliable to 
establish. 
4) The tendon reflexes were classified as normal, decreased, slight 
contraction visible and no contraction (the worst score was used). 
The use of aminoglycosides was noted at entry. The use and dosage of 
midazolam, vecuronium and steroids was registered on every neurological 
examination. The creatinine phosphokinase. erythrocyte sedimentation rate 
and liver functions were tested weekly. If a patient developed clinical or 
electrophysiological signs of a neuromuscular disorder the presence of 
myoglobin in the urine was analyzed. 
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Monitoring severity of underlying disease and infections (n=98): 
At entry of the study the Apache-III score, sepsis severity score and presence 
of SIRS were determined. Developing SIRS during the stay on the ICU was 
also noted. The Apache-III score, the Acute Physiology, Age, Chronic Health 
Evaluation, is a methodology that is known to predict hospital mortality risk 
for critically ill hospitalized adults [Friedland 1996, Knaus 1991]. The score 
results from addition of three groups of variables concerning physiology, age 
and chronic health. The physiology is represented in weighted laboratory 
abnormalities and vital signs: pulse, mean bloodpressure, temperature, 
respiratory rate, Pa02 , hematocrit, white blood cell count, creatinine, urine 
output, blood urea nitrogen, sodium, serum albumin, bilirubin, glucose 
[Knaus 1991]. 
The sepsis severity score consists of scoring the function of five organ 
systems (lungs, heart, liver, kidneys, intestine) and of the blood coagulation 
on a scale of 0 to 5 of which 5 reflects the worst situation. Eventually the 
three highest of these six scores are squared and summated resulting in the 
sepsis severity score (minimum 0 and maximum 7 5) [Stevens 1983]. The 
presence of SIRS includes two or more of the following clinical 
manifestations: (1) body temperature greater than 38°C or less than 36°C; 
(2) heart rate greater than 90 beats per minute; (3) tachypnea, manifested by 
respiratory rate greater than 20 breaths per minute, or hyperventilation as 
indicated by PaC02 ofless than 32 mm Hg; and (4) alteration in the white 
blood cell count, such as a count greater than 12,000/ cu mm, a count less 
than 4,000/ cu mm, or the presence of more than 10 percent immature 
neutrophils [Bone 1992]. 
Electrodiagnostic studies before, at time of diagnosis and during follow-up 
(n=98): 
Electrophysiological investigations were performed at day 4, 11 and 25 after 
start of the artificial respiration. The examination consisted of conventional 
orthodromic motor (ulnar and peroneal) and antidromic sensory (ulnar and 
sural) nerve conduction studies. The compound muscle action potential 
(CMAP) was recorded using a surface tendon-belly montage over the 
abductor digiti ntinimi for the ulnar nerve and over the extensor digitorum 
brevis in case of the peroneal study. The ulnar nerve conduction study was 
performed at the wrist, below and above the elbow and for the peroneal 
nerve at the ankle. fibular head and at the knee. Using this method pressure 
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palsies of the ulnar or peroneal nerve could be excluded. Furthermore 
repetitive nerve stimulation at 3 Hz with train counts of sLx of the ulnar 
nerve and concentric needle electromyography (EMG) of the biceps, 
abductor digiti quinti, quadriceps femoris and tibialis anterior muscle were 
performed. Spontaneous muscle fiber activity scored in rest and; motor unit 
potential on voluntary activation was described as normal, neuropathic, 
myopathic, or unclassifiable for testing. 
Once patients fulfilled the clinical and electrophysiological criteria of CIPNM 
a somato-sensory evoked potential were performed of the median nerve 
stimulating at the wrist and tibial nerve stimulating at the knee. Data from 
the conduction studies, repetitive stimulation, motorscore and tendon 
reflexes were used for analysis only if no vecuronium (neuromuscular 
blocking agent) was administered. 
Muscle biopsy: 
In 3 0 patients an open biopsy from the quadriceps muscle was taken from 
the leg opposite to the site on which the needle EMG was performed. 
Standard light microscopic analysis was used to classify the muscle tissue as 
myopathic, neuropathic or showing both characteristics (mbced). 
Statistical analysis; 
Part I: Clinical features 
The analysis was performed to describe the clinical features of CIFNM. 
Therefore the motor sum score, sensory symptoms, muscle wasting and 
tendon refle:xes were judged over time until discharge from the hospital or 
death. The statistical analysis of the motor sum score and tendon reflexes was 
performed only if patients did not use vecuronium for at least three days 
prior to analysis. 
Part II: Electrophysio1ogical features 
From the conduction studies the compound muscle action potentials (CMAP) 
and conduction velocities of the ulnar and peroneal nerve, the sensory nerve 
action potentials (SNAP) and conduction velocities of the ulnar (sensory) and 
sural nerve measured for all patients were interpolated to predefmed days. 
Therefore the scale t= -10, 0, 10,20,30 and 40 days was used of which t=O 
stood for time of diagnosis of CIPNM. Besides for the total group of CIPNM 
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patients, analysis of the conduction study was also performed for each 
motor sum score group separately. For the patients without CIPNM the 
values of the distal CMAP amplitudes and the SNAP amplitudes of the ulnar 
and sural nerve were determined on day 4, II and 25 of the artificial 
respiration. For the EMG the presence of spontaneous muscle fiber activity 
and changes in the motor unit potentials were analyzed on t=-1 (time 
before diagnosis CIPNM). t=O and t>l (time after diagnosis CIPNM) using 
chi-square test. The CMAP amplitude of the ulnar nerve recorded after wrist 
stimulation was correlated with the presence of spontaneous muscle fiber 
activity using the random effects logit model. This was also performed for 
the sum score of the CMAP amplitude of the ulnar nerve (wrist) and the 
peroneal nerve (ankle). 
The statistical analysis data of the GV!AP amplitudes were performed only if 
patients had stopped using vecuronium for at least three days. 
Part III: assessment of prognostic factors 
For the planned analysis of the prognostic factors of CIPNM the motor sum 
score was used for further correlation. After fifty days of follow-up the 
CIPNM group showed different subgroups of patients defmed as: 
I) Recovered CIPNM with no functional disability and motor sum score " 
26. The score of 26 was chosen because a lower score meets the clinical 
criteria of CIPNM [De Letter 200 I]. 
2) The motor disability group with motor sum score between I 0 and 26 and 
3) A group with early mortality and therefore period of follow-up that was 
too short to perform statistical analysis. 
The motor sum score groups I and 2 were used for further correlation v.ith 
the presence of sensory symptoms, muscle wasting and improvement of 
tendon reflexes using Pearsons chi-square test. This was also performed for 
age, sex, duration of artificial respiration, Apache-III score, sepsis severity 
score, SIRS. the standard light microscopical changes of the muscle biopsies 
and the total amounts of vecuronium and steroids used on day seven of the 
artificial respiration. 
A comparison was made of the creatinine phosphokinase in the serum of the 
CIPNM patients with the 6 6 patients without CIPNM. 
The results of the standard light microscopy (neuropathic, myopathic or 
mixed changes) of the muscle biopsies were correlated with the presence of 
spontaneous activity in the muscle fibers using the random effects logit model. 
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RESULTS 
Part I: Oinical features 
The general characteristics of 21 (group 1 and 2) of the 31 patients with 
CIPNM are listed in table 1. Seventeen (55%) of the 31 CIPNM patients died 
in comparison to 19 (29%) of the 66 patients that did not develop CIPNM 
(P=O.O 1 ). There was full recovery in 6 (20%) and persistent disability in 15 
( 48%) of the 31 CIPNM patients after 50 days of follow-up. All patients 
showed flaccid quadriplegia, the minimum motor sum score was zero. 
Follow-up of the motor sum score during the first month of the stay on the 
ICU is shown in the figures la-b. For all 31 patients the mean duration of 
the artificial respiration was 21 days. The mean duration in the recovered 
CIPNM group and the motor disability group was 14 and 23 days 
respectively (Table 1). In group 1 all patients were alive after one month on 
the ICU, in groups 2 mortality was 7/15 (47%) (P =0.06). 
Patients did not mention sensory complaints during the monitoring. The 
presence of muscle wasting and recovery of tendon reflexes showed no 
significant differences between the motor sum score subgroups 1 and 2. 
In the CIPNM patients the mean serum creatinine phosphokinase was 23 and 
in the group of patients that did not develop CIPNM 27 mmol/1. (not 
significanty different). 
Part II: Electrophysiologic features 
Follow-up of the CMAP (Fig 2a-b) and SNAP amplitude after stimulation of 
the ulnar nerve showed a decrease towards t=O (time of diagnosis CIPNM) 
and a gradual increase afterwards for the motor sum score subgroups 1 and 
2. The minimum CMAP amplitude of the abductor digit quinti muscle after 
stimulation at the wrist for the MRC sum score groups 1 and 2 were 3.52 
mV and 2.69 mV respectively. In the patients that did not develop CIPNM 
(n=66) on day 4, 11 and 25 of the artificial respiration this was SmV, 5 mV 
and 8 mV respectively. For the CMAP amplitude after stimulation of the 
peroneal nerve and the SNAP amplitude after stimulation of the sural nerve 
on every interpolated moment in time decreased values were found (Table 
2). The mean CMAP amplitude of the extensor digitorum brevis muscle after 
ankle stimulation in the patients that did not develop CIPNM (n=66) on day 
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Table!: Clinical features of patients suffering from CIPNM (n = 31). 
MRC-score MRC-score Overall 
<:: 26 <::10-<26 P-value 
Group 1 Group 2 
Motorscore in time 6 (20%) 15 (48%) 
Numbers of deaths 0 7 (47%) 0.06 
Muscle wasting 5/6 (83%) 14/15 (93%) 0.50 
Recovery tendon refle..xes 4/6 (67%) 8/15 (53%) 0.66 
Age (years) 60 68 0.48 
Se." (M/F) 4/2 10/s 1.00 
Duration artificial respiration (days) 14 22 0.17 
Apache-ill score 79 8 0.26 
Sepsis severity score 25 19 0.56 
Presence SIRS 4 (67%) 7 (47%) 0.41 
Use of vecuronium until day 7 2 7 0.66 
(x patients) 
Use of steroids =til day 7 0 5 0.26 
( x patients) 
Number muscle biopsies 5 15 
Standard light microscopy: 0.21 
-myopathy 4 5 ll 
- neuropathy 6 10 
- mL"\.ed 0 4 8 
respectively. Moreover these 66 patients showed a decreased median SNAP 
amplitude after stimulation of the ulnar and the sural nerves. On day 4, 11 
and 25 of the artificial respiration the values for the ulnar nerve after wrist 
stimulation were 10.63 J1V, 10.07 J1V and 9.33 ,uV. For the sural nerve these 
values were 5.57 J1V, 4.10 JlV and 6.60 JlV respectively. 
Conduction velocities of the ulnar nerve, peroneal nerve (until t= 20 days in 
the distal part of the lower leg) and sural nerve were normal during the 
period of monitoring on the intensive care unit. In one patient evidence was 
found for a superimposed pressure palsy of the peroneal nerve across the 
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fibular head showing a significant decrease of the conduction velocity. 
Repetitive stimulation of the ulnar nerve showed no abnormal decrement. 
The EMG of the biceps muscle showed no spontaneous muscle fiber activity, 
however for the abductor digiti quinti, quadriceps femoral and anterior tibial 
muscle spontaneous muscle fiber acti,ity increased significantly over time. At 
the time of the first needle EMG the abductor digiti quinti and anterior tibial 
muscle already showed spontaneous activity of the muscle fibers. In the 
quadriceps femoral muscle sucb early spontaneous activity was found in 2 of 
25 patients. From the second needle EMG on spontaneous activity of the 
muscle fibers was present in the abductor digiti quinti and anterior tibial 
muscle in 14 of 28 patients (P= 0.003) and for the quadriceps femoral 
muscle in 9 of 28 patients (P=0.03!). During EMG monitoring this activity 
disappeared in a proximal to distal gradient. The analysis showed no 
relationship between the CMAP amplitude of the ulnar nerve and the 
presence of spontaneous activity of the muscle fibers. Polyphasic motor unit 
potentials were present in all muscles examined without signs of a proximal-
distal gradient in time. 
Neuropathic or a combination of neuropathic and myopathic changes in the 
standard light microscopy of the muscle biopsies was related with the 
presence of spontaneous activity of the muscle fibers (P=0.029) and 
polyphasic motor unit potentials with increased duration (P=0.037). 
Somato-sensory evoked potentials were normal in all 2 2 CIPNM patients that 
were tested. 
Part III: Assessment of prognostic factors using subgroups 1 and 2. 
In both motor sum score groups muscle '"rasting and recovery of tendon 
reflexes were present and did not correlate with the clinical severity of 
CIPNM. The outcome did not relate to age, sex, duration of artificial 
respiration, Apache-IIJ score, sepsis severity score, SIRS, the use of 
vecuronium or steroids until day seven of the artificial respiration and with 
the results of the standard light microscopical examination of the muscle 
biopsies. Although no significant relationship was found, age and Apacbe-IIJ 
score were higher in group I compared to group 2. 
34 





" t :;" 12 ~ < 
' 
" ~ 10 ~ ~ 
0 u 8 ] ' " I ~ I ~ ~ 6 .s 










"0 0 2 
-20 -10 0 10 20 30 40 50 
Figure 2a. T= 0; time of diagnosing CIPNM (days) 
16 group 2 
> g 14 
0 
" > M 




"' 10 "3 c 0 
I " ·u ., ' I 3 u 8 e-~ u ~ .S 6 a. ~ < ~ ~ "' 4 0 "0 u 
" ~ • I 
'0 2 l 
0 
8 0 
-20 -10 0 10 20 30 40 50 
Figure 2b. T= 0; time of diagnosing CIPNM (days) 
35 
OW'Tiffi III 
Table2: Interpolated data of the conduction studies of 3 1 patients suffering 
from CIPNM. t= 0. is time diagnosis CIPNM. 
t=-10 t=O t=lO t=20 
(days) (day,;) (days) (days) 
CMAP amplitude abd dig v muscle (mV) 
-wrist 4.03 2.69 4.08 5.81 
-below elbow 3.26 2.44 3.25 4.70 
-above elbow 2.77 1.94 2.70 4.79 
CMAP amplitude abd dig br muscle (mV) 
-ankle 0.22 0.40 0.57 0.33 
-fibular head 0.15 0.27 0.42 0.29 
-above knee 0.18 0.19 0.49 0.42 
Sum CMAP amplitude abd dig v muscle 
(wrist) & abd dig br muscle (ankle) 4.87 3.34 4.19 5.81 
nerve (mV) 
Conduction Velocity ulnar nerve (m/ s) 
-wrist-below elbow 50.19 47.84 49.98 52.69 
-across ulnar sulcus 42.58 46.80 50.00 50.00 
Conduction Velocity peroneal nerve (m/s) 
-ankle-fibular head 39.98 37.70 36.94 27.90 
-across fibular head 36.22 37.34 44.85 34.16 
SNAP amplitude ulnar nerve (micro V) 
-wrist 7.26 6.64 9.01 11.64 
SNAP amplitude sural nerve (micro V) 
-lower leg 1.85 2.74 5.89 5.06 
Conduction Velocity sural nerve (m/s) 
-ankle-lower leg 38.93 35.43 33.66 35.28 
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DISCUSSION 
Part 1: Clinical features 
Development of CIPNM 
Ibis study shows that most patients were detected early in the course of the 
disease and some died already within the first two weeks of follow-up. These 
patients may be missed in earlier studies, since EMG was usually performed 
at a later stage. During the monitoring testing of motor function was 
influenced by severe underlying illness, the use of sedatives and 
neuromuscular blocking agents. This underlines the role of the 
electrophysiological study regarding the early detection of CIPNM. 
Recovery of the tendon reflexes and the presence of muscle wasting are 
important features of CIPNM without significant differences in the motor 
sum score groups. Zifko et al observed muscle wasting in 1/3 of the 62 
patients suffering from CIPNM [Zifko 1998]. We found that testing of 
tendon refle.xes is not a useful tool in the early diagnosis of CIPNM because 
of the use of neuromuscular blocking agents in the acute phase of critical 
illness. Patients did not mention sensory complaints during clinical 
monitoring, however prior to diagnosis of CIPNM sedation or the severity of 
the underlying illness could cause these symptoms to remain unnoticed. 
Particularly if the presence of such disturbances occurs in only a short period 
of time or is of minor severity compared with motor symptoms. Zifko et al 
[1998] also found that in 17 (27%) of the 62 patients with CIPNM reliable 
information on sensation could be obtained. Ten of them had distal, 
symmetric hypesthesia. Berek et al also described the difficulties to clinically 
confmn sensory symptoms [Berek 1996]. 
As expected, determination of the serum creatinine phosphokinase did not 
differ significantly with the patient group that did not develop CIPNM. 
Therefore the serum creatinine phosphokinase appears not useful in 
diagnosing CIPNM and should be tested only when an acute myopathy is 
suspected. 
Prognosis and recovery of CIPNM 
The outcome of the CIPNM patients is related directly to the prognosis of the 
underlying critical illness. Since the prognosis of patients with multiple organ 
failure is poor; a significant number of the patients (about 50-60%) will die 
37 
ffiAPTER III 
from the underlying critical illness. Previous reports on the prognosis of 
CIPNM are rather optimistic [Hund 1996, Leijten 1995], the overall mortality 
rates vary in prospective studies from 36% [Leijten 1995] to 55% in our 
study. The patients who survive usually recover from critical illness 
polyneuropathy and it has been stated that the long-term outcome is good. In 
five patients from the motor disability group who were willing to inform us 
about their functional status disability had recovered one year after discharge 
from the hospital however clinical and electrophysiological details are lacking. 
Leijten et al [1995] found that 5 of 8 (63%) patients with delayed recovery 
beyond 4 weeks after discharge from the ICU still had a persistent motor 
handicap after one year. Zifko [2000] studied eleven of 13 surviving patients 
with CIP 1-2 years after the onset of the disease. Five of them had signs of 
mononeuropathy and quality of life was seriously impaired. Their 
electrophysiological features revealed abnormalities in the motor, sensory and 
phrenic conduction studies. De Seze et al [2000] analyzed the critical care 
conditions and 2-year clinical follow-up of 19 patients who suffered from 
severe forms (quadriplegia or quadriparesis) of CIP. Characteristics of patients 
who recovered clinically were compared with those of patients who did not. 
Two patients died within 2 months, II recovered completely, 4 remained 
quadriplegic and 2 remained quadriparetic. All patients suffered from sepsis, 
MODS and a catabolic state before the onset of CIP. Outcome appeared 
difficult to predict with clinical or electrophysiological data. Three variables 
were significantly correlated to poor recovery: longer length of stay on the 
critical care unit, duration of sepsis and loss of body weight. 
Part II: Electrophysiological features 
The electrophysiological data show both motor and sensory axonal 
dysfunction in the upper and lower extremities. Clinically the motor 
dysfunction is much more evident. Previous prospective studies also found 
such electrophysiological features [Latronico 1996, Witt 1991, Zochodne 
1987, Coakley 1993]. however the findings of Hund et al [1997] revealed 
normal SNAP amplitudes. As the SNAP amplitudes after stimulation of the 
ulnar and sural nerve in the 66 patients without CIPNM were also decreased, 
the sensory findings in the CIPNM and the non-CIPNM patients should be 
considered as unreliable in the diagnosis of CIPNM. Furthermore we note 
that electrophysiological follow-up of the lower extremities was often 
technically difficult and unreliable due to edema. This explains the lack of the 
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pattern, which was found during follow-up of the CMAP amplitude after 
stimulation of the peroneal nerve or the sum CMAP amplitude of the 
abductor digiti quinti and abductor digitorum brevis muscle. Therefore the 
motor conduction study of the upper e.:tremities should be primarily used in 
diagnosing patients that are at risk for developing CIPNM. The pattern of the 
CMAP amplitudes in time (until t= 50 days) as mentioned above showed 
complete recovery in the recovered CIPNM group and decreased values in 
the motorscore disability group. The EMG of CIPNM patients contained the 
most pronounced spontaneous muscle fiber activity in the distal muscles 
with a proximal to distal gradient during recovery of the clinical and 
electrophysiological dysfunctions. Together with the results of the 
conduction study these were mainly features of an axonal (senso) motor 
polyneuropathy. The latter was sustained by the correlation of spontaneous 
muscle fiber activity and the presence of neuropathic changes or both 
neuropathic and myopathic changes in the standard light microscopical 
examination of the muscle biopsies. The EMG signs of acute spontaneous 
muscle activity are one of the features of CIPNM [Hund 1996]. The problem 
of testing myopathic changes of the motor unit potential is mainly due to 
the inability of voluntary contraction in these patients. Mostly the myopathic 
changes in C!PNM are found in the muscle biopsies [Latronico 19 9 6, De 
Letter 2000a, Op de Coul 1991]. To discriminate neuropathy from 
myopathy by means of the EMG Rich et al [1997] already described the use 
of direct muscle stimulation. In case of myopathy the muscle remains 
electrically inexcitable. At the time of our study this method was not yet 
available. 
During CIPNM no dysfunction of the neuromuscular junction was found, 
reflected in the normal response after repetitive nerve stimulation. Nor are 
there significant disturbances of the spinal dorsal columns in CIPNM as the 
somato-sensory evoked potentials were normal. 
Part III: Assessment of prognostic factors using subgroups 1 and 2. 
The clinical variables age, sex and duration of the artificial respiration 
showed no relation with the motor sum score groups. Furthermore the 
severity of critical illness reflected in the Apache-III score, the sepsis severity 
score or the presence of SIRS was not related with these groups either. We 
however note the gradual increase of the Apache-III score in the relatively 
small subgroups from the recovered CIPNM group (I) towards the motor 
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disability group (2). Thusfar these parameters only play a role as risk factors 
[Bolton 1996, De Letter 2001]. The use ofvecuronium or steroids did not 
correlate with the severity of CIPNM. 
Nor did the specific structural changes in the muscle biopsies of the patients 
correlate with the motor sum score groups. Earlier we mentioned the lack of 
a relation between the use of medication as vecuronium, steroids and 
midazolam with the standard light microscopical findings [De Letter 2000a]. 
Only few data from prospective studies provide suggestions that might 
influence the natural history of CIPNM. Therapeutically the importance of an 
early start of rehabilitation therapy in CIPNM patients has been described 
[Leyten 1995]. De Seze et al [2000] described the apparent relationship 
between the severity of CIP and that of sepsis and its associated 
hypercatabolism. The authors recommended aggressive measures against 
sepsis to limit CIP and its sequelae. We also emphasize the possibility of 
therapeutic strategies in CIPNM. As local (muscle tissue) low-level immune 
activation was demonstrated to play a role in CIPNM, immune therapy 
should be considered. Previous results from treating patients in the early 
phase of sepsis with immunoglobulins intravenously were promising, the 
incidence of CIPNM decreased dramatically [Mohr 1997]. This study was 
however retrospective and could have suffered from a selection bias. We 
suggest that patients at risk for developing CIPNM may be better off with 
immunoglobulin treatment, whereas treatment after CIPNM has developed 
appeared to be unsuccessful [Wijdicks 1994]. The early treatment option 
should however be tested in a proper trial. 
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Immune activation in CIPNM 
IVa How critical illness may trigger a powerful immune cascade in 
patients in the intensive care unit 
!Vb Immune activation in the muscle tissue of patients with CIPNM 
CHAPTER IV 
IVa HOW CRITICAL ILLNESS MAY TRIGGER A POWERFUL 
IMMUNE CASCADE IN PAT!El\TTS IN THE INTENSIVE CARE UNIT 
Muscle biopsies from patients in the intensive care unit are yielding 
important new clues to the basic mechanisms involved in their critical illness 
polyneuropathy and myopathy. By discovering what drives the disease 
process, new investigations could have a sharp impact on therapies of the 
future. 
Recently, progress has been made in the understanding of the basic 
mechanisms involved in critical illness polyneuropathy and myopathy 
(CIPNM). This is of great importance as polyneuropathy and myopathy are 
frequently encountered in patients in the intensive care unit. Despite this 
progress, however, the pathophysiological basis of this entity is largely 
speculative and involves histological and serologic analysis of these disorders. 
Although many explanations for the polyneuropathy and myopathy associated 
with critical illness initially looked promising, investigators have failed to link 
such neuromuscular problems with the extensive use of neuromuscular 
blocking agents, steroids, aminoglycoside antibiotics, and specific nutritional 
deficiencies. New studies include critical illness as the likely cause of a 
cascade of inflammatory events culminating in nerve and muscle disease. 
Biochemical changes are well-recognized manifestations of the sepsis and 
multiple-organ failure syndrome [Bolton 1993d]. Such disturbances and the 
accompanying immunological activity in the microcirculation of various 
organs in sepsis could contribute to a growing appreciation of mechanisms 
that could underlie a primary axonal degeneration. These recent studies have 
focused on the fact that blood vessels supplying peripheral nerve lack auto-
regulation, rendering them particularly susceptible to such disturbances 
[Bolton 1996). As this recognition has gained favour, researchers have 
directed their attention to the series of events leading to the influx of 
potentially inflammatory cells, including monocytes/macrophages, 
neutrophils, and CD4+ (helper T) cells. As part of this hypothesis, renewed 
attention has also been given to cytokines because cytokines secreted in sepsis 
have histamine-like properties that may increase microvascular permeability. 
Cytokines have important functions in inflammatory processes, as both up-
regulating and down-regulating factors and are likely to participate in the 
inflammatory process of myopathies [Lundbergl997). The inflammatory 
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cascade in inflarrnnatory myopathies has also been described in a number of 
recent reports, notably by Dalakas [1995] who suggests that when activated, 
the CDS+ cells (cytotoxic T cells) recognize antigens presented in the context 
of MHC class l molecules whereas the CD4+ cells recognize antigen 
presented by the MHC class 11-bearing cells. Some of the CD4+ cells can 
interact with the B-lymphocytes via various lymphokines to produce specific 
antibodies. 
NEUROLOGICAL AUTOIMMUNE DISEASE: HOW THE CASCADE 
BEGINS 
Generally triggering of an immune response occurs in the circulation and 
lymphoid tissues but outside the nervous system. T cells play a key role in 
the regulation of these inunune responses but also as effector cells generated 
during the response~ Dysregulation occurs in T cells that normally are self-
tolerant. Once they no longer become self-tolerant, they are activated and 
capable of recogiD.Zing various auto-antigens within the nervous system 
[Dalakas 199 5]. Although the nature of these molecules is largely unknown 
and consequently, the antigenic specificity of these auto-reactive T cells has 
yet to be determined, the following key processes are proposed to be 
involved (Fig I): 
• Cytokines. During a viral or bacterial infection cytokines are released as a 
consequence of the induced inunune response and play an important role 
in changing T cell tolerance to self-antigens. When an auto-antigen in the 
circulation is presented to a T cell by the antigen-presenting cells such as 
macrophages in the lymphoid organs, these macrophages release certain 
cytokines (interleukin IL-6, IL-l) that are able to stimulate T cells. 
Generally, quiescent auto-reactive T cells lose their tolerance to the self-
antigens and become activated by the combined presence of the antigen 
and the cytokines. Even if the infectious agent is missing from the T cell, 
the released cytokines provide enough stimulation to activate these T cells 




Infection triggers molecular mimicry. The concept of molecular mimicry may 
explain what occurs when an infectious agent shares epitopes with host 
antigens. Viral or bacterial antigens sharing epitopes with the central or 
peripheral nervous system induce an immune response consisting of 
antibodies and sensitized T cells specific for the infectious agent but also 
cross reacting vvith auto-antigens. In dermatomyositis, for example, it has 
been postulated that an auto-antibody or immune-complex-mediated 
response against vascular endothelium might be the primary pathogenic 
mechanism. Also essential to understanding the pathophysiology of this 
disease is the deposition of membrane attack complex (MAC) due to the 
activated complement cascade on the vascular endothelium. Secondary to 
microvascular damage is the influx of potentially inflammatory cells, like 
monocytes/ macrophages, neutrophils, and CD4+ helper T cells. 
• T helper cells. Naive CD4+ I helper T lymphocytes (Th) develop into 
functionally mature effector cells upon stimulation with relevant antigenic 
peptides presented on the major histocompatibility complex (MHC) class 
II molecules by antigen-presenting cells (APC). Based on the characteristic 
set of cytokines produced, Th cells are commonly segregated into at least 
two different subpopulations: Thl cells and Th2 cells. These Thl and Th2 
subsets appear to be extremes in cytokine production profiles and within 
these polarized subsets, individual Th cells e:illibit differential rather than 
coordinated cytokine gene expression. These subsets develop from 
common Th precursor cells (Thp) after triggering with relevant pep tides 
into ThO cells producing an array of cytokines, including IL-2, IL-4, IL-5 
and IFN-y. These activated ThO cells subsequently polarize into the Thl or 
Th2 direction based on the cellular and cytokine composition of their 
microenvironment. Antigen-presenting cells like the various subsets of 
dendritic cells besides subsets of macrophages largely determine this 
polarization into Thl or Th2 subset development. The Thl-Th2 subsets 
appear to cross regulate each other's cytokine production profiles, mainly 
through IFN-y and IL-l 0, and from this concept it was rationalized that 
disturbances in the balance between these two subsets may result in 
different clinical manifestations. IL-12 is a dominant factor promoting Thl 
subset polarization and dendritic cells and macrophages produce JL-12. 
Moreover, IL-12 induces IFN-Y production by T cells and natur<il. killer (NK) 
cells. Recently, it was reported that IL-18 acts synergistically with IL-l 2 to 
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induce Thl development [Tewsl996]. Polarization of Th2 cells is 
critically dependent on the presence of IL4 produced by T cells or 
basophils and mast cells. APC-derived IL-6 has also been shown to induce 
small amounts of IL-4 in developing Th cells. IL-l 0 and APCderived 
prostaglandin E2 (PGE2) inhibit IL-12 production and Th! priming 
[Nakamura 1997]. The Thl-Th2 paradigm has been useful in correlating 
the function of Thl cells with cell-mediated immunity (inflammatory 
responses. delayed type hypersensitivity. and cytotoxicity) and Th2 cells 
with humoral immunity. In general. among infectious diseases. resistance 
to intracellular bacteria. fungi. and protozoa is linked to mounting a 
successful Th I response. Th I responses can also be linked to pathology. 
like arthritis. colitis and other inflammatory states. Effective protection 
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Fig 1. Hypothetical representation of possible rclcvmt interactions in the immunopathology of CIPKM. 
An as yet unidentified ,.hit" influences the activity of antigen-presenting cells (APC), including 
presentation of (auto) antigens to specific T cells and cytokinc production. As a result, the Thl-Th2 
balance vv:ilJ. be disrurbc:d, leading to activity of the Thl cclls and possible stimulation of muscle cclls to 
act as (non-professional) APC. - = inhibiting effect; ?= as yet unresolved issue. 
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THE IMPACT OF NEW FINDINGS: CLUES TO THE 
PATHOPHYSIOLOGY OF CIFNM 
The new results have added clues for an immune-mediated process in critical 
illness polyneuropathy and myopathy. Inflammatory infiltrates found in the 
biopsies of these patients presented as either small clustered infiltrates or 
isolated inflammatory cells and were comprised mainly of macrophages and 
CD++ lymphocytes, not CDS+ cells or B cells. The evidence for IL-l, 
TNF£XR7 S and IFN-y in muscle fibers lends support to previous work by 
Tews et a! [1996] who suggested that the expression of these cytokines by 
muscle fibers in inflammatory myopathies may induce and mediate the 
process of autoimmunization and antigen expression without the primary 





Fig 3.- Possible mechanisms for septic encephalopathy and critical illness polyneuropathy. Arrows 
pointing to the curved hne indicate mechanisms that may apply to both central and peripheral nervous 
system. Lower arrows designate treatments that may affect these systems independently. The heavy 
arrows highlight the most likely mechanisms. Release of cytokines from macrophage and from T 
lymphocytes may directly affect the brain or act directly on the blood-brain barrier and microcir-
culation. Encephalopathy may also be due to the failure of other organs or to direct infection of the 
brain with formation of microabscesses. Critical illness polyneuropathy may be due to disturbance of 
microcirculation of peripheral nerve through effects similar to those in brain. Various treatment may 
play a role as well in triggering pathophysiology. 
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because this cytokine could be a powerful activator of the immune cascade 
and induces the proliferation of T cells. Overall, the immunological fmdings 
support the hypothesis that local low-level immune activation seems to be 
important in patients with CIPM. These critically ill patients suffer from 
severe organ dysfunction, tissue damage or severe infections resulting into 
sepsis or multiple organ dysfunction syndrome (MODS). All these factors 
could trigger immune activation eventually leading to damage of the nervous 
system. Hopefully new data will confirm and expand upon the results 
obtained so far. Armed with this information, investigators will be able to 
tackle the issue of tailoring therapeutic strategies with more confidence 
because they understand the basic mechanisms involved (Fig3). 
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IVb IMMUNE ACTIVATION IN THE MUSCLE TISSUE OF 
PATIENTS WITH CIPNM 
INTRODUCTION 
Critical illness polyneuropathy and myopathy (CIPNM) can be encountered in 
critically ill patients during or after (prolonged) artificial respiration. The 
clinical features are difficulty in weaning from the ventilator. generalized 
wasting of the limbs with severe tetraparesis, hypo- or areflexia and 
prolonged rehabilitation. Electromyographical examination reveals abundant 
denervation potentials compatible with an axonal polyneuropathy and often 
low and short amplitudes compatible with a myopathy [Bolton 1984, Op de 
Coul 1985, Zochodne 1987]. On clinical and electrodiagnostic grounds 
neuromuscular complications in the critically ill patients may be due to a 
polyneuropathy or myopathy. Since it is not always possible to differentiate 
between an axonal motor neuropathy and myopathy, we prefer to use the 
term critical illness polyneuropathy or myopathy (CIPNM). 
Severe cases of CIPNM should be distinguished from the acute motor axonal 
variant of Guillain-Barre syndrome. Other diagnostic considerations include 
damage to anterior horn cells resulting from acute or chronic spinal cord 
ischemia and acute motor neuropathy associated with administration of 
nondepolarizing neuromuscular blocking agents [Hund 1997]. The following 
conditions have been associated previously with CIPNM: prolonged artificial 
respiration with the usage of neuromuscular blocking agents, systemic 
inflammatory response syndrome (SIRS), multi organ failure (MOF), and 
treatment with high dose steroids or with aminoglycosides [Bolton 1993d, 
Boltoni996J. But the etiology of CIPNM has not been elucidated thusfar. 
We have postulated that cytokines such as TNF-<X and IL-6 may be involved 
in the pathophysiology of CIPNM, but no convincing evidence was found 
after analyzing their serum [Verheul 1994]. However, there may well be a 
local process of immune activation. Therefore in this study the presence of 
immune activation was investigated in the muscle tissue. Bazzi et al studied 
muscle biopsies of two patients with an electrophysiological diagnosed as 
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critical illness myopathy. Immunohistochemical analysis revealed a positive 
reaction for Hl.A-I and staining for membrane attack complex (MAC). In one 
muscle biopsy single lymphocytes were present but no cellular infiltrates. 
They concluded that their patients could be affected by an autoimmune-
inflammatory myopathy [Bazzi 1996]. 
In a large prospective study we analyzed the incidence of this neuromuscular 
disorder and investigated the hypothesis whether local immune activation in 
muscle tissue could play a role in the development of CIPNM. 
METHODS 
Patients 
From May 1994 to July 1996 98 patients were included in a longitudinal 
prospective observational study held at the intensive care unit of the St. 
Elisabeth Hospital Tilburg. The medical ethical committee (MEC) of the 
hospital approved the study and a written informed consent was obtained 
from the family of the patient. 
Patients could be included if they needed at least three days of artificial 
respiration. All patients included in the study were monitored clinically and 
neurophysiologically for the development of CIPNM. Exclusion criteria for 
follow up in this study were the presence of the Guillain-Barre syndrome, 
acute or chronic spinal cord lesion, hypophosphatemia, myasthenia gravis 
and a history of polyneuropathy or myopathy. In addition patients younger 
than 15 years of age were not admitted. 
This neurological examination was performed twice weekly and 
neurophysiological monitoring on day 4, 11 and 25 after starting artificial 
respiration. Clinically CIPI'-<'M was defmed as severe tetraparesis with wasting 
of the limbs and hypo- or areflexia at least three days after the use of 
neuromuscular blocking agents. The severity of the paresis consisted of a 
MRC sum score < 26 (maximum 30) of the three upper and three lower 
limb muscles that were tested. The neurophysiological study consisted of 
conventional motor (ulnar and peroneal nerve) and sensory nerve (ulnar and 
sural nerve) conduction studies. Further repetitive nerve stimulation at 3 Hz 
of the ulnar nerve and monopolar needle electromyography of two muscles 
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of the upper and lower limb respectively (EMG). In cases of CIPNM this 
study shows an a.xonal polyneuropathy with or without signs of a myopathy. 
Ibis results in a reduction of the compound motor action potential (CMAP) 
and the sensory nerve action potential (SNAP) and only a mild reduction of 
the conduction velocities. The needle electrode study shows signs of acute 
denervation with fibrillation potentials and positive waves in the resting 
muscle. In those cases of critical illness myopathy the motor unit potentials 
have low amplitude and a short duration. To define a patient as having 
CIPNM the clinical and the neurophysiological descriptions as mentioned 
above had to be met. 
In 30 of the 32 patients with CIPNM and 2 of the 66 patients without 
CIPNM controls an informed consent was obtained to perform an open 
biopsy from the quadriceps femoral muscle. Ibis was taken at least three days 
after stopping treatment with neuromuscular blocking agents and in cases of 
CIPNM within 3 days after the diagnosis. No permission was given by the 
MEC to perform a nerve biopsy. The two control patients also needed 
artificial respiration, they were severely ill. like the CIPNM group of patients, 
and were therefore matched controls. They did not show clinical or 
neurophysiological signs of CIPNM. One of the control patients suffered from 
Goodpasture's disease, the other from severe hyperglycemia. To avoid 
artefacts the biopsy was always taken from the leg opposite to the site at 
wbich the EMG was performed. The biopsies were frozen and stored at -70° 
C until analysis. The immunohistochemical analysis was performed at the 
Erasmus University Rotterdam. 
Standard light microscopy and immunohistochemical analysis 
Standard light microscopic and immunohistochemical analyses were 
performed. For the latter, a streptavidiii-biotin method was used with a broad 
panel of antibodies [Hoefakker 199 5]. Briefly, cryostat sections ( 6)1) were 
fixed for I 0 minutes in buffered formaline I 0% pH 6.9. After blocking using 
human serum the slides were incubated with a monoclonal antibody. All 
reagents were titrated to acbieve optimal results. Subsequently the slides were 
incubated with biotinylated goat anti-multilink (Biogenex) containing normal 
human serum 2% and normal goat serum 2%. Enzyme detection was carried 
out after incubation with streptavidin biotin alkaline phosphatase. First 
napthol as-mx (Sigma) 18 mg and TRIS-HCL 60 ml pHS.O (Sigma) and 
secondly fuchsine 200 pl and sodium nitrate 200 pl were mixed. Finally 
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levamisole 15 mg (Sigma) was added. After staining the reaction was 
stopped and counterstaining with haematoxylin was performed. 
The mouse monoclonal antibodies (MoAb IgG) as listed in table 1 were used. 
For immunohistochemical analysis of cytokines we used the MoAb VHP20 
recognizing human IL-lf, a rat MoAb 2-4A1 recognizing human IL-12 p40 
and a rat MoAb recognizing human IFN-y, all of the IgG class. Additionally a 
rabbit polyclonal antibody recognizing human TNFaR7 5 was used. 
Two different controls for our staining method were performed. First, 
control staining of the sections with an isotype-matched control antibody 
without the primary antibody. In these controls no staining was seen. 
Secondly, positive and negative tissue controls were used to verify the 
specificity of the staining in every staining procedure. The negative control 
was a muscle biopsy of the quadriceps femoral muscle from a healthy 
subject. A muscle biopsy from a patient with dermatomyositis served as a 
positive control for the analysis of CD4, CDS, CD20, CD68, E-selectin, 
!CAM, VCAM, HLA-1, HLA-DR and TNFaR75. Muscle tissue from a patient 
with polymyositis was used as a positive control for MAC and IL-12. For IL-
1{3 and IFN-y a skin biopsies from patients with psoriasis and for E-selectin a 
human tonsil served as a positive control. 
Interpretation of the biopsies 
Scoring of the standard light microscopic and the immunohistochemical 
analysis was performed separately by a neuropathologist and two 
experienced neurologists. The classification was carried out without 
knowledge of the clinical or laboratory data of the patients or the controls. 
Thereafter the results were discussed. The biopsies were classified as primary 
neuropathic, myopathic or mixed as defmed by Dubowitz [1985]. For the 
immunohistochemical analysis the following classification was used; 
stallings were scored as negative (-)I not present or positive (+)I present. 
Oinical findings 
The neuropathological findings were compared with clinical and laboratory 
parameters using the erythrocyte sedimentation rate (ESR), creatine 
phosphokinase (CK) and the sepsis severity score in the CIPNM group at 
entry. 
The sepsis severity score consists of scoring five organ systems (lungs, heart, 
liver, kidney, intestine) and the coagulation on a scale of 0 to 5 of which 5 
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Table I: Listing of the antibodies used, including the dilution and their 
source. 
CD-marker Dilution Source 
Inflammatory cells 
Th-cells CD4 I: I 00 Becton Dickinson. Mountain View, 
CA 
Tc-cells CDS 1:75 Becton Dickinson, Mountain View. 
CA 
B-e ells CD20 1:400 Biogene:<, San Ramon, USA 
Macrophages CD68 1:300 DAKO. Glostrup, Denmark 
Aclliesion molecules 
Eselektin CD62E l :50 DAKO. Glostrup. Denmark 
ICA\1-1 CD 54 1:25 Neomarkers. Fremont. USA 
VCAM CD106 1:25 DAKO. Glostrup. Denmark 
Complement molecule 
MAC (C5b-9) l :50 DAKO. Glostrup. Denmark 
Proinflammatory cytokines 
IL-l ,6 1:20 E. Claassen, Erasmus University 
Rotterdarn,NL 
IL-12 l: l 0 E. Claassen, Erasmus University 
Rotterdarn,NL 
IFN y 1:40 W.A. Buurman, University 
Hospital Maastricht,NL 
TNF<XR75 1:25 W.A. Buurman, University 
Hospital Maastricht."l. 
Anti-inflarrunatory cytokine 
IL-10 1:250 ]. Laman, Erasmus University 
Rotterdam.NL 
Antigen presentation 
HLA-1 l :2000 E. Claassen, Erasmus University 
Roterdam, Nl 
HLA-DR l: l 00 Becton Dicldnson, Mountain View. 
CA 
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reflects the worst situation. Eventually the three highest of these six scores 
are put to a square and summated resulting in the sepsis severity score 
(minimum 0 and maxlinum 75) [Stevens 1983]. 
Statistical analysis 
The distribution of the standard light microscopic findings related to the 
results of the linmunohistochemistry was compared using the Kruskal Wallis 
test. Percentages of the linmunohistochemical findings in the CIPNM group 
(n=30) and the two control biopsies were compared with Fisher's exact test. 
Differences in ESR and sepsis severity score between the CIPNM patients and 
the 66 patients without CIPNM were tested with the Mann-Whitney test. 
This test was also used to analyze a possible pattern of the ESR and sepsis 
severity score in the neuropathological changes in the CIPNM group. P-
values <0.05 were considered significant. 
RESULTS 
Incidence 
CIPNM was diagnosed in 32 of the 98 (33%) patients who underwent 
prolonged artificial respiration, leaving 6 6 patients without CIPNM 
Histology 
Standard light microscopic e.xarnination showed neuropathic changes in 3 7% 
(II/30), myopathic changes in 40% (!2/30) of the patients and both 
neuropathic and myopathic changes in 23% (7 /30) of the patients, without 
overlap between the groups. Muscle fiber necrosis was only present in 3 0% 
(9/30) of the muscle biopsies, showing a sparse and scattered pattern. There 
was no relation between the presence of muscle fiber necrosis and the level 
ofCK. 
The effect of high dose steroids inducing pure myopathy with loss of type-II 
muscle fibers and fast myosine was present in one patient with an 
exacerbation of her COPD and was e.xcluded from the CIPNM group. 
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Immunohistochemical analysis 
Immunohistochemical analysis showed small infiltrates containing 10 to 20 
inflammatory cells in 27% (8/30) of the biopsies. The perivascular infiltrates 
consisted of different celltypes all expressing CD68 and CD4 and less 
frequently CDS (3% (1/30)) and were located within the perimysium. 
Additionally, isolated macrophages were seen scattered in the perimysium 
and near necrotic muscle fibers when present. Overall, macrophages (CD68) 
were found in 40% (12/30) of the biopsies (Fig. 1a). CD4 positive cells 
were present in 60% (18/30) in the perimysium, usually in the perivascular 
region and sometimes in the endomysium. CD20 positive B-cells could not 
be detected. 
In all biopsies there was an upregulation of HLA-1 and HLA-DR. HLA-1 was 
strongly present on the surface of all nucleated cells compared with muscle 
biopsies of inflammatory myopathies (positive controls) and a normal muscle 
biopsy (negative control). HLA-DR was positive on the surface of the nucleus 
of the muscle fibers and on the vascular endothelium. In general infiltrates 
contained HLA-DR positive cells (Fig. 1 b). 
ICAM-1 and VCAM staining were positive in 58% (15/26) and 53% (16/30) 
of the biopsies respectively on the peri- and endomysia! vascular endothelium 
(Fig. 1c). On the other hand E-selectin staining was negative in all CIPNM 
biopsies. It however was positive in the tonsil. 
MAC was present in 79% (21/28) of the biopsies being found mainly on the 
vascular endothelium and on necrotic muscle fibers when they were present 
(Fig. 1 d). Positive MAC staining was not associated with perivascular 
infiltrates (data not shown). 
TNFCiR75 cytoplasmic staining was found in 90% (27 /30) of the biopsies on 
the vascular endothelium and diffuse juxtanuclearly in the muscle fibers (Fig 
1e). IL-1,8 staining was present in 71% (20/28) of the biopsies and showed 
diffuse juxtanuclear cytoplasmic staining in the muscle fibers (data not 
shown). IFN-y was positive in 40% (1 0/25) of the biopsies. Morphological 
analysis revealed these IFN-y positive cells to be lymphocytes and not other 
cell types since these were not detected in any of the biopsies analyzed. 
Surprisingly IFN-y also showed staining in the juxtanuclear cytoplasm in the 
muscle fibers (Fig. 1f). IL-10 was present in 96% (27/28) of the biopsies 
both on the vascular endothelium (Fig 1 g) and the cytoplasm of cells that 
were located mainly perivascularly in small clusters. 
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IL-12 staining was positive in 73% (19/26) of the biopsies in the cytoplasm 
of cells with a horseshoe-like nucleus containing a spot, which were shown 
histo-morphologically to be monocytes located in the perimysium (Fig. 1h). 
The two control biopsies showed the presence of HLA-1 on nucleated cells. 
In the muscle biopsy from the patient with Goodpasture's disease the 
endothelium of some capillaries stained with ICAM-1 and VCAM. 
Only very minor interobserver differences were found. After discussing 
without knowing the patients data agreement was achieved in _all cases. Not 
all 3 0 muscle biopsies could be tested for the complete panel of antibodies 
due to lack of sufficient muscle tissue, these are marked as unknown in 
table 2. The results of antibody staining in the CIPNM biopsies were not 
significantly correlated with the outcome of the standard light microscopy. 
But the presence ofHLA-DR (100%), TNFaR75 (90%) and IL-10 (96%) in 
the muscle biopsies of the CIPNM patients was significantly higher compared 
with the two control biopsies (0%). This resulted in P-values of 0.002, 0.02 
and 0.007 respectively. 
The ESR and the sepsis severity score showed no significant differences 
between the CIPNM group and the patients that didn't develop CIPNM or a 
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Fig. la: 
Macrophages (CD68) near a necrotic muscle fiber (red staining). 
b 
Fig. lb: 
HIA-DR staining on the vascular endothelium (red staining). 
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Fig. lc: 
VCAM is present on the endothelium of a blood vessel (red staining). 
d 
Fig. ld: 










The arrows point at IFN-y staining juxtanuclear in the cytoplasm of a muscle 
fiber (red staining). The juxtanuclear production of this cytokine makes it 
look like a nuclear staining. 
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Fig. lg: 
IL-10 is present on the vascular endothelium (orange-brown staining). 
,h t_ __ 
Fig. lh: 
IL-12 staining is positive in the cytoplasm of a cell with a horseshoe-like 
nucleus containing a basophilic spot (red staining), histomorphologic 
characteristics of a monocyte. 
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In this study we found evidence for local immune activation in patients 
suffering from CIPNM. This disease is clinically characterized by muscle 
weakness, which may be related to inflammatory factors. This infiltration 
presents itself either as small clustered infiltrates or by the presence of 
isolated inflammatory cells. These cells are comprised mainly of macrophages 
and CD4+ lymphocytes, not of CDS+ cells or B-cells. The macrophages and 
CD4+ cells showed an activated phenotype (HLA-DR-positive) as other cell 
types were not present. Equally, these inflammatory cells are more likely to 
be responsible for the observed production of proinflammatory and anti-
inflammatory mediators. 
In the same muscle biopsies we found evidence for expression of several 
adhesion molecules on the vascular endothelium. This is consistent with a 
model explaining the infiltration of the muscle tissue. Lundberg et al. already 
postulated the importance of the endothelial cells in inflammatory 
myopathies (IM). The presence of IL-Ia on the vascular endothelium may 
lead to the induction of endothelial cell adhesion molecules. In IM this can 
result in the extravasation of inflammatory cells [Lundberg 1997]. 
Moreover, MAC-positive staining was seen on the endothelium and on 
necrotic muscle fibers, when present. The expression of MAC initiates 
capillary destruction and increases vascular permeability [Hohlfeld 1994]. 
The site and the size of the inflammation do not reflect a strong pathological 
stimulus leading to the heterogeneity in the standard light microscopy as 
found here and which was described previously [Zochodne 19 8 7, Al Lozi 
1994, Coakley 1993, Subramony 1991, Danon 1991, Gutmann 1996, 
Wokke 1988, Op de Coul 1991, Latronico 1996]. The weak, but persistent 
inflammatory response is accompanied by the release of proinflammatory 
and anti-inflammatory mediators. In our study IL-1,6, TNFaR75 and 
surprisingly also IFN-y were expressed by muscle fibers. Tews et al. 
postulated that the ""-'Pression of cytokines (IL-Ia and -,6, IL-2 and TNFa) by 
muscles fibers in inflammatory myopathies may induce and mediate the 
process of autoimmunization and antigen-expression without the primary 
presence of inflammatory cells [Tews 1996]. We found the presence of 
tissue damage in the biopsies of the CIPNM patients. This is possibly due to 
MAC-induced capillary destruction, and occasionally by necrotic muscle 
fibers which may' explain the abundant expression of HLA-DR positive cells. 
We speculate that these endothelial cells and scattered macrophages could 
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present these potential auto-antigens to the migrating CD4+ T -cells. Bazzi et 
al studied the expression of HLA-I, CD4, CDS, CD19 and MAC in two 
patients with CIPNM and could not find cellular infiltrates. In one patient 
CD4, CDS and CD19 positive staining was present. Both cases however also 
showed HLA-I upregulation and scattered microvascular deposits of MAC 
suggesting that at least some patients with CIPNM could be affected with an 
autoimmune-inflammatory myopathy [Bazzi 1996]. 
The production of IL-l 2 by monocytes as recognized histomorphologically 
could be considered a powerful activator of the immune cascade and induces 
the proliferation ofT-cells. A possible effect of IFN-y could be the expression 
of HLA-DR on the surface of the vascular endothelium and macrophages as 
we found in our study. IFN-y also sustains the activation of macrophages, 
and the production of proinflammatory cytokines, which leads to an 
upregulation of adhesion molecules on the vascular endothelium [Debets 
1996]. We demonstrated the expression of ICAM-1 and VCAM, the adhesion 
molecules that induce increased vascular permeability. E-selectin is 
synthesized rapidly after cell stimulation by cytokines and is present in severe 
inflammation. The absence of severe inflammation in the current study may 
explain why we did not find positive staining on the vascular endothelium 
for E-selectin. 
The immune activation seen in the muscle tissue was associated with minor 
infiltrates with some inflammatory cells observed in only 27% of the 
biopsies. The size and relatively low percentage of inflammatory cells were 
unlikely to be due to a sampling error as there were no biopsies that showed 
larger infiltrates or infiltrates with celltypes other than CD6S, CD4 and less 
frequently CDS positive cells. On the other hand there seems to be a role for 
anti-inflammatory cytokines, as demonstrated by the abundant expression of 
IL-l 0. In our opinion the presence of IL-l 0 could prevent severe 
inflammation in the muscle tissue, eventually leading to reconvalescence. 
To support the hypothesis that the presence of immune activation in the 
muscle tissue was due to CIPNM and not to an inflammatory process 
elsewhere in the body, it was important to analyze matched controls. We 
were fortunate to get muscle biopsies from two such patients. They were 
critically ill, on the artificial respirator and died shortly after the biopsies 
were taken. One patient suffered from Goodpastures disease, an immune 
mediated illness in which immune activation could be expected. The other 
had severe hyperglycemia and multi organ failure (MOF), which means that 
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systemic immune activation was present in this patient. Therefore these 
patients were relevant controls. The importance of local immune activation 
and the presence of both a pro- and anti-inflammatory stimulus in muscle 
tissue of CIPNM patients is shown in the role of HLA-DR, TNFaR7 5 and IL-
l 0 that differ statistical significantly from the control biopsies. The small 
control group of two patients implies a wide 95% confidence interval of the 
percentages of HLA-DR positive, TNFaR7 5 positive and IL-l 0 positive 
patients, namely 0%-84%. These intervals for the CIPNM patients are 88%-
100% (HLA-DR positive), 73%-98% (TNFaR75 positive) and 82%-100% 
(IL-l 0 positive). Especially the results for HLA-DR, representing immune 
activation in the muscle tissue of CIPNM patients, with non-overlapping 
confidence intervals are an indication of a statistically significant outcome. 
Other arguments against non-specific changes in the muscle tissue of CIPNM 
patients, resulted from the fact that the distribution of the erythrocyte 
sedimentation rate and the sepsis severity score did not differ between the 
CIPNM patients and the patients without CIPNM (n=66). And the level of 
the ESR or the sepsis severity score did not correlate with specific structural 
changes in the muscle biopsies of the CIPNM patients. We postulate that 
systemic or local (as yet unresolved) factors are required to cause the local 
immunohistopathological changes as described in the muscle tissue of our 
CIPNM patients. 
In conclusion, our findings support the hypothesis that local low level 
immune activation seems to be of importance in patients with CIPN~. The 
release of cytokines may have contributed to the clinical and 
electrophysiological findings of a neuropathy and/ or myopathy. Factors 
causing tissue injury may trigger macrophages, leading to the production of 
cytokines and temporary T-cell-activation. The e.'--pression of ICAM-1, VCAM 
and MAC suggests the possibility that increased vascular permeability could 
play a role. We propose that together these processes lead to damage of the 




Discussion: a pathogenetic model of CIPNM 
and future directions 
DIAGNOSIS OF CIFNM 
The results of our study indicate that critically ill patients with a high 
Apache-III score and presence of SIRS are most prone to the development of 
CIPNM. Clinical and electrophysiological criteria are used for diagnosing 
CIFNM. In previous studies general definitions of axonal polyneuropathy 
were used but never defined specific towards CIPNM. Therefore this study 
provided such criteria (Chapter II) using variables of the clinical and 
electrophysiological examination of ICU patients that are teclmically reliable. 
Also factors as the use of neuromuscular blocking agents and the level of 
consciousness of the patient were taken into account. 
In the near future it is important to reach an international consensus for the 
clinical and electrophysiological criteria of CIPNM. The following criteria are 
proposed, which are open for discussion. 
DIAGNOSTIC CRITERIA OF CIFNM 
Assessment of clinical findings 
Clinical assessment is reliable when patients have not been exposed to any 
neuromuscular blocking agents for at least three days. For diagnosis of 
CIPNM both clinical and electrophysiologcal criteria should be met. 
Clinical; present in at least tvvo consecutive visits. 
Co-operative patient 
Motor sum score <26. 
• Decreased or absent tendon reflexes. 
Non co-operative patient. 
No reaction to pain stimulus or discrepancy between facial movements 
and movement of the extremities vvith ·motor sum score < 8 
• Decreased or absent tendon refle..xes. 
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Electrophysiological; 
Presence of axonal polyneuropathy: 
I distal CMAP of the ulnar nerve is absent or below <4.2 mV and 
entrapment at the elbow and demyelination* is e:xcluded. 
and 
distal CMAP of the peroneal nerve is absent or below <2.6 mV and 
entrapment at the fibular head and demyelination* is excluded. 
II Criteria for ulnar or peroneal nerve as mentioned above 
and 
Spontaneous activity in rest (fibrillations or positive waves) in at least two 
of the examined muscles using needle electromyography. 
*) Ratio of the area of the proximal CMAP versus the distal CMAP >0.89, 
in the nerve with decreased CMAP amplitude. 
There is need for further evaluation of the exact incidence of critical illness 
polyneuropathy, myopathy or the combination of the two in the ICU 
population. The fmdings distal muscle weakness (with or without the 
presence of facial muscle weakness) and sensory loss differentiate critical 
illness polyneuropathy from critical illness myopathy clinically with mainly 
proximal musle weakness. Other tools are electrophysiological testing using 
direct muscle stimulation and muscle biopsy for more detailed 
discrimination. At this stage it is my opinion that most of the patients have a 
combination of peripheral nerve and muscle involvement resulting in 
CIPNM. 
RISK FACTORS 
The highest incidence of CIPNM of about 70%, if patients suffer from sepsis 
or SIRS as found in earlier studies, is supportive for the type of risk factors 
(SIRS and Apache-III score) found in this study that attribute to the 
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development of CIPNM. However, there are drawbacks to these two scoring 
systems. The criteria of SIRS are met rather easily and the Apache scoring 
system is very complex, consisting of general characteristics and physiological 
features. To minimize these disadvantages of the scoring methods each organ 
system was also analyzed separately using the components of the sepsis 
severity score. This however did not reveal a relation with the development 
of CIPNM. Most important the statistical analyses showed that SIRS and the 
Apache III score contributed both independently to the multivariate Cox 
regression. 
IMMUNE MECHANISMS 
It is clear that immune mechanisms are involved in MODS and SIRS and our 
findings indicate that immune activation is present in CIPNM, although 
immunohistochemistry was only assessed in muscle tissue and not in 
peripheral nerve. 
At present investigators are still far from defining the specific pathogenetic 
factors of CIPNM. Thus far in the immunohistochemical analysis of this study 
a model was described for patients suffering from severe trauma, burns or 
sepsis, patients that underwent major surgery or combinations as possible 
triggers of the immune system. 
In this thesis the immunohistochemical study of muscle biopsies of CIPNM 
patients a comparison could only be performed with two biopsies of patients 
that did not develop CIPNM. Ethical aspects limit the performance of biopsies 
in patients without CIPNM. Therefore in future studies serum analysis of 
soluble immunological parameters ( cytokines, adhesion molecules etcetera) 
may be another method to investigate the role of immune activation in 
CIPNM patients. If future studies confirm the presence of (local) immune 
response therapeutic strategies using immune-modulating therapy could be 
developed. These may then influence the course of CIPNM or prevent it from 
occurring, which needs to be tested in a prospective randomized placebo 
controlled trial. Electron microscopical examination of the muscle tissue 
could also add important information in describing specillc structural changes 
as for example to the thick filaments, which enables the discrimination of 
CIPNM from acute quadriplegic myopathy. 
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FOLLOW-UP 
This study had a relatively short follow up of the natural history of CIPNM 
patients with a relatively small number of patients that survived. High 
mortality is due to the fact that the severity of critical illness was high. The 
occurrence and prognosis of the polyneuropathy is considered to be related 
to the prognosis of the underlying critical illness. Since the prognosis of 
patients with multiple organ failure is fatal in about 50-60% of the patients, 
a significant number of patients will die from the underlying critical illness. 
This study supports the hypothesis that in some patients CIPNM is an 
additional factor in the organ failure and contributing to the persistent severe 
illness, resulting in death. The patients who survive usually recover from 
critical illness polyneuropathy and in general the long-term outcome is 
considered to be good. However, the residual fmdings in CIPNM are 
underestimated. As for long term follow-up very few data are available 





Summary I Samenvatting 
Q-L'J':"ER VI 
Critical illness polyneuropathy and myopathy (CIPNM) is a neuromuscular 
disorder encountered in the !CU. During critical illness patients develop 
muscular weakness of the limbs with atrophy. Respiratory muscles and 
occasionally cranial nerves are involved and tendon refle..xes are decreased or 
absent. The electrophysiological features include an axonal polyneuropathy 
and possible myopathic changes in the needle electromyographic 
examination. Neuropathological findings in nerve and muscle tissue show 
either neuropathic, myopathic changes or both. The entity CIPNM has been 
recognized first in the early eighties. Chapter I describes the characteristics 
mentioned above more elaborately, furthermore the variants and differential 
diagnosis of CIPNM is discussed. A large prospective study on CIPNM also 
studying patients on the ICU under the same conditions that did not develop 
CIPNM had not been performed thus far. This was the goal of this thesis 
including the following subjects: the risk of development of CIPNM (chapter 
II), its natural history (chapter III), the neuropathological features including 
variables involved in immune activation (chapter N -J and constructing a 
model on the pathogenesis and possible therapeutic strategies (chapter V). 
Chapter II describes 9 8 patients that were on the artificial respirator were 
studied of whom 3 2 developed CPNM. To diagnose CIPNM clinical and 
electrophysiological criteria were defined, which both had to be met. From 
several patients characteristics multivariate analysis showed that a high 
Apache-III score (p=0.02) and the presence of SIRS (p=0.04) in the early 
phase of the stay at the ICU differed significantly between the group of 
patients that developed CIPNM (32 patients, 33%) and those that did not (66 
patients, 67%). Medication as midazolam, vecuronium, steroids and 
aminoglycosides did not play a role as risk factor for the development of 
C!PNM. Based on the distribution of the predictive index derived from the 
variables Apache-III score and SIRS three risk groups were identified. The 
low-risk group with an Apache-III score ,;yo and no SIRS, the high-risk 
group with an Apache-III score >8S and presence of SIRS and the medium-
risk group containing the other patients. The Kaplan-Meier curves show that 
the probability of developing CIPNM within 30 days of artificial respiration is 
8% for the low-risk group, 28% for the medium-risk and 72% for the high-
risk group. 
In chapter III both clinical and electrophysiological features of 3 I of the 3 2 
patients with C!PNM were analyzed. After SO days follow-up of 6 of the 31 
C!PNM patients (19%) had a good functional recovery and IS of the 31 
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patients (48%) showed persistent motor disability defmed as poor outcome_ 
The ten other CIPNM patients died early after inclusion. The clinical and 
electrophysiological features were compared with the study population that 
did not develop CIPNM (66 patients)- Overall mortality in the CIPNM group 
was 55% and 29% for the patients that did not develop CIPNM (p=O.Ol). 
After six months l 0 patients of the poor outcome group still had motor 
disability. 
The main tools for the clinical diagnosis of CIPN~ are assessment of muscle 
weakness using the MRC sum score and assessment of tendon reflexes as 
mentioned in the diagnostic criteria for both co-operative and non co-
operative patient (Ch II). The electrophysiological criteria can be met earlier 
in time than the clinical criteria of CIPNM. Assessment of muscle weakness 
was often not reliable because of the severe underlying illness and use of 
neuromuscular blocking agents. These factors may also explain why we did 
not fmd sensory complaints clinically. Using EMG conduction studies, CMAP 
amplitudes of the nerves of the upper e.--memities together with needle EMG 
are the most reliable measurements to diagnose CIPNM as edema of the 
lower limbs is often a problem in ICU patients. In patients without edema 
the SNAP amplitude of the sural nerve was decreased in most cases and 
therefore supportive for the diagnosis of CIPNM ( Ch II)_ Needle EMG 
showed spontaneous activity of the muscle fibers mainly in the distal muscles 
of the limbs (p=0.003) comparing the first recording (day 4 of the artificial 
examination) with the second examination (day ll of the artificial 
respiration)_ Spontaneous activity of the muscle fibers was related with 
neuropathic or both neuropathic and myopathic changes in the muscle 
biopsies of the CIPNM patients (p=0.029). Conduction velocities were 
normal during monitoring on the !CU. One patient had superimposed 
pressure palsy of the peroneal nerve across the fibular head. SSEP of the 
median and tibial nerve was tested in 2 2 patients with CIPNM and were all 
normal. 
No prognostic factors were present after statistical analysis of the patients' 
characteristics, their medication, the Apache-III score, SIRS, severity of sepsis 
or light microscopical fmdings when comparing two groups with good or 
poor outcome during follow-up. Age and Apache-III score were higher in 
the poor outcome group, but the differences were not significant. 
After an introduction on the mechanism of immune activation during critical 
illness, chapter N describes a neuropathological study of the muscle tissue of 
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3 0 of the 3 2 patients with CIPNM and 2 patients that did not develop CIPNM 
during prolonged artificial respiration. In the muscle biopsies of the CIPNM 
patients neuropathic changes were found in 37%, myopathic in 40%, and a 
combination in 23%. The immunohistopathology showed macrophages and 
Thl-cells in 40% and 60% of the muscle biopsies respectively. Small mainly 
perivascular infiltrates were present containing macrophages and Th !-cells. 
ICAM-1, VCAM and MAC were found on the vascular endothelium in 58%, 
53% and 79% of the muscle biopsies respectively. In all biopsies of the 
CIPNM patients there was an upregulation of both HLA-1 and HLA-DR. 
Proinflammatory cytokines and TNFaR7 5 were also produced locally (IL-1,8 
in 71%, IFN-y in 40%, IL-12 in 73%, TNFaR75 in 90%). The anti-
inflammatory cytokine IL-l 0 was expressed simultaneously in 9 6% of the 
biopsies. HLA-DR, TNFaR7 5 and IL-l 0 differed significantly when compared 
with the muscle biopsies from the patients that did not develop CIPNM. 
These data show that small numbers of activated leukocytes producing both 




Critical illness polyneuropathie en myopathie (CIPNM) is de neuromusculaire 
aandoening die patienten ontwikl::elen, die ernstige orgaanfunctie stoornissen 
hebben en daarmee de benaming "critically ill" verdi en en. Deze patienten 
zijn veelal afhankelijk van kunstmatige beademing en onder deze conditie 
ontwikkelen zij een aandoening van het perifere zenuws.telsel. Een dergelijke 
aandoening vertoont kenmerken van algehele zwakte aan de extremiteiten en 
van de ademhalingsmusculatuur , de spieren zijn atrofisch en spierrek-
kingsreflexen zijn verlaagd of a:fwezig. Soms kunnen ook de hersenzenuwen 
meedoen, hetgeen zich veelal uit in aangezichtszwakte en oogbewegings-
stoomissen. Het gaat dus om een klinisch beeld van met name het motore 
deel van het perifere zenuwstelsel, maar ook sensibele functiestoornissen 
bestaande uit hypaesthesie/ gevoelsverlies of paraesthesieen/tintelingen 
kunnen aanwezig zijn. In dit laatste geval pleit de kliniek voor een 
polyneuropathie. Het aanvullend onderzoek in de vorm van 
electromyografie/EMG bevestigt een dergelijke polyneuropathie wanneer de 
amplituden na stimulatie van de motore en eventueel ook de sensibele 
zenuwen verlaagd zijn en er bij naald-electromyografie in rust sprake blijkt te 
zijn van spontane spiervezelactiviteit. Er is dan sprake van een axonale 
(senso)motore polyneuropathie. Mocht er desondanks onvoldoende 
diagnostische duidelijkheid zijn, dan is ook de betrokkenheid van de 
intercostaalmusculatuur of de nervus phrenicus te testen. De myopathische 
component is veelal terug te vinden in het spierweefsel, waarbij standaard 
lichtmicroscopisch onderzoek van spierbiopten veranderingen toont bij 
sommige patienten die passen bij een myopathie. De spiervezels zijn daarbij 
veelal atrofisch met een varierende diameter en rend aspect. Wanneer de 
structurele kenmerken voomarnelijk neuropathisch zijn dan zijn de spiervezels 
hoekig en atrofisch. Verder kunnen in een gevorderd stadium de type-I en 
type-IT spiervezels zich gaan hergroeperen door reillnervatie (type-grouping). 
Ook mengbeelden in het microscopisch onderzoek met myopathische en 
neurogene kenmerken zijn mogelijk. 
CIPNM werd begin jaren tachtig onderkend en voor het eerst beschreven 
door de pioniers Dolf Op de Coul en Charles Bolton. Sedertdien volgden 
voomamelijk casuistische en retrospective publicaties. Deze postuleerden 
beschreven en retrospectieve analyses postuleerden verschillende patho-
genetische factoren voor CIPNM. In dit proefschrift wordt een prospectieve 
studie beschreven waarin patienten gemonitord worden op het ontwikl::elen 
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van CIPNM (hoofdstuk II) en het beschrijven van verscheidene aspecten van 
de aandoening (hoofdstukken III, N en V). 
In hoofdstuk I wordt ingegaan op de klinische en electrofysiologische 
kenmerken van CIPNM. Daarnaast worden de varianten en differentiaal 
diagnose van CIPNM beschreven. 
Hoofdstuk II beschrijft de analyse van de risico factoren voor het 
ontwikkelen van CIPNM. Van de 98 patienten die kunstmatig beademd 
werden voided en er 3 2 gedurende de follow-up aan zowel de klinische als 
electrofysiologische criteria van CIPNM. In de speurtocht naar risico factoren 
voor het ontwikkelen van CIPNM werd uitgegaan van een drietal 
categorieen: I) medicatie in de vorm van sedativa, spierverslapping, 
steroiden en aminoglycosiden, 2) aanwezigheid van SIRS (systemic 
inflammatory response syndrome) en de sepsis severity score en 3) Apache-
III score (Acute Physiology Age and Chronic health Evaluation score), een 
gewogen score van algemene patient karakteristieken en fysiologische 
parameters. De statistische analyse toonde dat de genoemde medicatie niet als 
risico factor aan te merken was voor het ontvvikkelen van CIPNM. Na 
multivariate cox-regressie analyse bleken de aanwezigheid van SIRS (p=0.04) 
en een hoge Apache-III score (p=0.02) wei significante risicofactoren. AI in 
de vroege fase van de beademingsperiode bleek er een significant verschil 
voor deze twee parameters voor patienten die CIPNM ontwikkelden (3 2 
patienten, 33%) en patienten waarbij CIPNM uitbleef (66 patienten, 67%). 
De sepsis severity score opgebouwd uit 5 orgaansysteemscores en een score 
voor de stalling bleek geen risico factor. Evenmin was dat het geval voor de 
6 componenten van deze score, die ook ieder apart werden geanalyseerd. 
V ervolgens werd een predicatieve index verkregen middels de hoogte van de 
Apache-III score en de aanwezigheid van SIRS voor het ontwikkelen van 
CIPNM. De !age risico groep heeft een Apache-III score s; 70 en geen SIRS, 
de hoge risico groep heeft een Apache-III score >85 en SIRS is aanwezig. In 
de medium risk groep zitten de overige patienten. De Kaplan-Meier curves 
tonen een kans voor het ontwikkelen van CIPNM binnen 30 dagen in de !age 
risico groep van 8%, voor de medium risk groep van 28% en een kans van 
72% voor de high risk groep. 
In hoofdstuk III wordt het natuurlijk beloop van 31 van de 3 2 patienten met 
CIPNM beschreven. Voor het stellen van de klinische diagnose bleken de 
motore somscore en de spierrekkingsrefle.xen de belangrijkste onderdelen van 
het neurologische onderzoek. Het feit dat sensibele klachten veelal niet vast 
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te leggen zijn, wordt veelal veroorzaakt door de mate critical illness en het 
gebruik van sedativa_ Het electrofysiologische onderzoek wordt vaak 
be1nvloed door het gebruik van spierverslappers en de mate van "critical 
illness" waarbij oedeem aan de extremiteiten het geleidingsonderzoek 
bemoeilijkt. In het geleidingsonderzoek zijn het meten van de CMAP 
arnplituden aan de bovenste extremiteiten en het naald-EMG het meest 
betrouwbaar voor het stellen van de electrofysiologische diagnose CIPNM. 
Na een follow-up van 50 dagen was er bij 6 van de 31 patienten (19%) een 
goed functioned herstel, 15 van de 31 patienten (48%) toonde nog steeds 
een motore handicap gedefinieerd als slechte outcome. De overige 10 
patienten overleden vroeg na de inclusie, waardoor zij niet mee konden 
worden genomen in de langere termijn statistische analyse. De klinische en 
electrofysiologische parameters van de twee groepen CIPNM patienten 
werden vergeleken met die van de 6 6 patienten zonder CIPNM. Overall was 
de mortaliteit voor de CIPNM groep 55% en de patient en zonder CIPNM 
29% (p=0.01). Na 6 maanden hadden patienten van de slechte outcome 
groep nog steeds een motore handicap van betekenis. Bij navraag bleek er na 
1 jaar van vijf ondervraagde patienten bij allen geen sprake meer van een 
functionele beperking in het dagelijks Ieven. Er bleken geen prognostische 
factoren voor het verloop van CIPNM na statische analyse van de Apache-III 
score, de aanwezigheid van SIR.S, sepsis severity score, medicatie in de vorm 
van sedativa, spierverslapping, stero1den en arninoglycosiden. 
Hoofdstuk IV geeft een introductie omtrent immuun activatie tijdens critical 
illness. Vervolgens worden de resultaten besproken van de weefsel studie in 
de vorm van standaard lichtmicroscopisch en immuunhistochemisch 
onderzoek van de spierbiopten van 3 0 van de 3 2 patienten met CIPNM en 2 
spierbiopten uit de groep van 66 patienten die geen CIPNM ontwikkelden. In 
het standaard lichtrnicroscopische onderzoek bleek de verdeling myopatische, 
neurogene afwijkingen en mengbeelden met kenmerken van beide verdeeld 
als 40%, 37% en 23%. De immuunhistopathologie van de patienten met 
CIPNM toonde de aanwezigheid van macrofagen en Th 1-cellen in 
respectievelijk 40% en 60%. Kleine perivasculair gelegen infiltraten bevatten 
macrofagen en Th1-cellen. Adhesie moleculen, die leiden tot een verhoogde 
permeabiliteit van de endotheel wand van de bloedvaten in de spiebiopten 
waren aantoonbaar in de vorm van ICAM-I in 58% en VCAM in 53%. Het 
membrane attack complex (MAC) was aanwezig in 79% van de spierbiopten 
en leidt eveneens tot een permeabeler endotheliale vaatwand. Alle biopten 
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van de CIPNM patienten toonden een verhoogde expressie van HLA-1 en 
HLA-DR, de human leucocyte antigens die tonen dat er sprake is van 
immuunactivatie in het onderzochte weefsel. Tevens werden cytokinen 
kleuringen verricht van zowel het anti- als pro-inflammatoire type, die de 
immuunactivatie respectievelijk remmen en stimuleren. Bij statistische analyse 
van de spierbiopten van CIPNM patienten en patienten die geen CIPNM 
ontwikkelden, bleek er een significant verschil voor de aanwezigheid van 
HLA-DR, het pro-inflammatoire cytokine TNF-alfa R7 5 en anti-inflammatoire 
cytokine IL-10. Deze verschillen en de homogeniteit van de bevindingen 
binnen de CIPNM groep leidden tot de conclusie dat een klein aantal 
geactiveerde leucocyten zowel pro- als anti-inflammatoire cytokinen 
produceren die het skeletspierweefsel infiltreren bij CIPNM patienten. De 
balans van anti- en pro-inflammatoire activiteit bepaalt behalve het ontstaan 
van de aandoening ook het eventuele herstel. Wat de uiteindelijke trigger is 
die leidt tot de beschreven immuun activatie is tot dusver speculatief en is 
mogelijk in de vorm de aanwezigheid van sepsis, multi-trauma, uitgebreide 
brandwonden, uitgebreide chirurgische ingrepen of combinaties ervan. Meer 
ondersteuning voor het pathogenetisch model zou verkregen l..'llll.Ilen worden 
indien bij herhaling de beschreven afwijkingen worden aangetoond. Verder 
suggereert de impact van de immuunactivatie, dat dit een ingang zou 
kunnen betekenen voor therapeutisch intervenieren. Een immuun-
modulerende therapie client echter in de vorm van een prospectief 
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omgaan en maakten de afronding van "de klus" mede mogelijk. 
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omstandigheden de mens in hem te ontdekken, die voorrang gaf aan 
stabiliteit in het prive Ieven. Hoezeer hij het volbrengen van het 
promotieonderzoek door mij ambieerde. die ruimte gaf hij oprecht. Heel 
bijzonder was het moment in het najaar 1999 toen Dolf en Charles Bolton 
elkaar konden ontmoeten en waarvan wij als Tilburgse CIPNM 
onderzoeksgroep getuigen waren. Charles, momenteel werkzaarn als professor 
in Neurology in de Mayo Clinics in Rochester Minnesota heeft me 
internationaal altijd gesteund tijdens de publicatieprocedures. Klinisch 
neurologisch wetenschappelijke tijdschriften heb ik eigenlijk niet kunnen 
enthousiasmeren tot het publiceren van de manuscripten. Op dergelijke 
momenten was Charles een raadsman en een aimabel mens. 
Ook Freek Verheul toonde zijn enthousiasme voor CIPNM en verrichtte een 
pilot studie, hetgeen een vlotte start van mijn prospectieve studie mogelijk 
maakte. Beste Freek dank voor je overtuigende begeleiding in de beginfase. 
De start van het onderzoek doet me ook stilstaan bij het intensive care 
personeel en de laboranten Klinische Neurofysiologie van het St Elisabeth 
ziekenhuis Tilburg, allen een onontbeerlijke spil om patienten te kunnen 
includeren. In het Tilburgse verdienen ook Hans Teepen, neuropatholoog, die 
zeer uitgebreid alle standaard bewerkingen van de spierbiopten heeft gedaan, 
Jacques van der Pas en Gerrit Gielen voor alle grafische inspanningen. mijn 
persoonlijke dank in dit proefschrift. 
Om onderzoek en opleiding te combineren met de nodige werkbezoeken aan 
de Erasmus Universiteit Rotterdam was flexibiliteit en back-up door mijn 
collega's/neurologen in opleiding onontbeerlijk: Freek Verheul, George 
Kienstra, Leo Canta, Peter Nijssen, Ben Jansen, Thorn Timmerhuis, Jeroen van 
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der Plas, Joost Jongen , Marleen Christiaans, Roy Beekman, Esther Brusse, 
Nicole Metz en Erik Lusseveld ontzettend bedankt. Ook mijn opleiders dr 
C.C. Tijssen en drs R.L.L.A. Schellens in het St. Elisabeth ziekenbuis Tilburg 
verdienen een plaats in deze dankzegging voor het uit dragen van hun 
enthousiasme om onderzoek te doen. 
Dr L.H. Visser, beste Leo, beste copromotor; met j ouw komst kon het 
uitvv .. erken van de resultaten naar de manuscripten en het proefschrift toe 
gestalte krijgen. ]e kennis en wetenscbappelijke ervaring zijn mede bepalend 
geweest voor de l:waliteit van het boek. J e hebt een onomstotelijk 
vertrouwen getoond in de waarde van het onderzoek. Maar ook persoonlijke 
ondersteuning was je niet vreemd en voor mij erg belangrijk. Leo, dank 
hiervoor en ik hoop in de toekomst samen met je verder research binnen het 
veld van CIPN"M te doen . 
Door Dolf Op de Coul werd voldoende vertrouwen gewekt bij prof. dr 
F.G.A. van der Meche, destijds hoogleraar Neurologie aan de Erasmus 
Universiteit Rotterdam, om mij te begeleiden en vorm te geven aan de 
studieopzet. Beste Frans, beste promotor; om naast mijn opleiding tot 
neuroloog aan je wetenschappelijke wensen te voldoen was intensief, maar 
met jouw inzicbten 1..-wam het onderzoek als gedegen van de vloer. Het heeft 
mijn opleiding verrijkt, waarvoor ik je mijn erkentelijkheid wil toeschrijven. 
Het laboratorium onderdeel van de studie brengt mij bij dr P.A. van Doom. 
Beste Pieter, je introduceerde mij op het laboratorium bij Frieda van der 
Ham een analiste uit duizenden, die mijn twee linker handen leerde coupes 
van de spierbiopten te snijden en immunhistocbemiscbe kleuringen te doen. 
Mijn zeer oprechte dank Pieter voor al die uren die je spendeerde aan het 
beoordelen van die resultaten en later aan het manuscript. 
Ook prof. dr H.F.]. Savelkoul hoogleraar immunologie te Wageningen liet 
mij geloven in de waarde van de testresultaten. Beste Huub ik ben van 
mening dat je het ook prima zou doen als "mental coach" en wens je alle 
waardering toe in je huidige functie. 
Dr ir P.l.M. Schmitz statisticus: Beste Paul als klinisch ingesteld onderzoeker 
was statistiek voor mij niet bepaald eenvoudig. Mijn verwondering was dan 
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ook bij herhaling groot wanneer je de waarde van de onderzoeksresultaten in 
maat en getal wist vorm te geven. Het was een tijdrovend geheel waarbij er 
in het overleg plaats was voor een persoonlijke noot, dank hiervoor. Met het 
noemen van Paul volgt vanzelfsprekend Kris Sieradzan: dank voor alle 
ondersteuning betreffende de computer programmatuur. 
Aan mijn collega's in het St Antonius Ziekenhuis Nieuwegein: Peter Siegers, 
Henk Mauser, Stephan Frequin en Oscar Vogels, dank voor de mentale steun 
en het vertrouwen in de slotfase. 
Betrokken bij de finishing touch van dit boek en als steun op rnijn promotie 
dag mocht ik rekenen op mijn paranimfen Caroline Heijckmann en Renske 
van den Berg-Vos. Jullie mag ik met recht onvoorwaardelijke vriendinnen 
noernen. 
Omdat het onmogelijk is een ieder persoonlijk te noemen die mij in de 
afgelopen jaren steunde in verschillende facetten van het onderzoek, een 
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